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ABBREVIATIONS 
ALL = Acute Lymphoblastic Leukaemia 
AML = Acute Myeloid Leukaemia 
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BMT= Bone Marrow Transplantation 
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CFU-F = Colony Forming Unit-Fibroblast 
CFU-GM = Colony Forming Unit-Granulocyte-Macrophage 
CML = Chronic Myeloid Leukaemia 
CSF-GM = Colony Stimulating Factor-Granulocyte-Macrophage 
Cy = Cyclophosphamide 
ECM = Extracellular Matrix 
Epo = Erythropoietin 
FCS = Foetal Calf Serum 
HC = Horse Serum 
HS = Heparan Sulphate 
IL= Interleukin 
MDS = Myelodysplastic Syndrome 
MNC = Mononuclear Cells 
MTx = Methotrexate 
NHL= non-Hodgkin's Lymphoma 
PBSC = Peripheral Blood Stem Cells 
SAA = Severe Aplastic Anaemia 
SCF = Stem Cell Factor 
TBI = Total Body Irradiation 
TGF-J3 = Transforming Growth Factor-J3 
TNI = Total Nodal Irradiation 
a.-MEM = a.-Minimal Essential Medium 
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ABSTRACT 
Recovery following bone marrow transplantation is associated with the reduction in the clonogenic potential of 
stroma-adherent CD34+ progenitors. The bone marrow stroma is also affected, resulting in poor support for the 
growth of stroma-adherent multipotent progenitors that form blastic colonies (CFU-bl). To determine the possible 
mechanisms of marrow damage in patients treated with peripheral blood stem cells (PBSCs) and bone marrow 
transplantation (BMT), we studied the effects of bFGF, a cytokine known to stimulate the survival and 
proliferation of fibroblasts, on the propagation of clonogenic progenitors and the marrow stroma. 
METHODS: In order to obtain the optimal bFGF concentrations to be used on patients' haematopoietic 
progenitors and bone marrow rnicroenvironment, haematologically normal individuals were studied in dose 
response studies. Control mononuclear cells from the Ficoll-Histopaque interface layer were divided into two 
aliquots: one to establish a stromal layer and to culture fibroblastic progenitors (CFU-Fs) in the presence of 0, 2 
and 20 ng/ml bFGF with and without 20 ng/ml heparan sulphate (HS). The second aliquot was for the selection 
of the progenitor population. Stroma was quantitated by placing culture dishes on a grid containing Imm squares 
and scoring the number of squares occupied by stromal layers as the percentage area covered. After 3 weeks of 
culture, a single cell suspension was prepared by incubation of stroma with 5% trypsin solution, and number of 
cells in the dishes enumerated with a particle counter. CFU-Fs were terminated on the 9th day of culture, stained 
with May-Grilnwald-Giemsa and scored using an inverted microscope. 
From the second aliquot, CD34+ cells were incubated with paramagnetic beads and target cells isolated with a 
magnet. Selected l x l 04/mJ cells were cultured on prefom1ed controls' stroma that has been treated with 0, 2 and 
20 ng/ml bFGF. Stroma-adhered cells were covered with 0.3% agar and cultured for 6 days. Aggregates of more 
than 20 cells were counted as CFU-bl. 
RESULTS: In normal individuals, the median surface area of the petri dish covered by stroma at 3 weeks of 
culture was 55% (range 30-65) and was significantly improved upon the addition of 2 ng/mJ (median 70%; range 
50-95 ; p= <0.05) and 20 ng/mJ bFGF (median 80%; range 65-99; p= 0.004). Stromal cell numbers were 0.61 x 
10612ml (range 0.15-1.66), and they increased significantly with the addition of 2 and 20 ng/ml bFGF (p=0.03). 
The median colony forming unit-blasts (CFU-bl) scores were 121.8 x 10
4/mJ (range 43-271), and they expanded 
significantly with the addition of 20 ng/mJ bFGF with and without heparan sulphate (p=0 .03 and 0.01). It was 
then concluded that the 2 and 20 ng/mJ bFGF with heparan sulphate be used on patients ' cells in vitro. 
In order to define the effects of the 2 and 20 ng/ml bFGF on the haematopoietic progenitors and on the bone 
marrow rnicroenvironment, 16 patients in remission from their haematological malignancies, who had received 
grafts, were studied employing the same methods used for the normal population. 
IX 
The median surface area covered by stromal layers in patients' samples at 3 weeks was 40% (range 0-55 vs. 
normal 50%), and it was in1proved significantly upon the addition of bFGF (median 78 vs. 50%; p= 0.001). 
Supplementation of stromal layers with bFGF accounted for a significant increase in patients stromal cell 
numbers (2.11 vs. normal 0.61 x I06/2ml; p< 0.05). Patients' CD34+ cells panned on normal stromal layers 
resulted in significantly fewer CFU-bl (median 40 vs. normal 90 x 10
4/ml CFU-bl; p=0.009), but CFU-bl 
numbers were corrected following the addition of bFGF, matching the scores achieved by normal individuals (85 
vs. normal 90 x l 04/ml). Normal CD34+ cells proliferated poorly on patients' stromal layers in the absence of 
bFGF (3 9 vs. normal 90 x 104/ml), but colony numbers increased significantly upon addition of bFGF (91 vs. 
normal 90 x 104/ml CFU-bl). 
Thirteen patients receiving peripheral blood stem cells (PBSCs) and nine patients undergoing bone marrow 
transplantation (BMT) were compared. These two stem cell sources were then compared to the normal 
population. Stromal layers in patients receiving PBSC grafts covered a greater surface area than the area covered 
in patients undergoing BMT (median 65 vs. 30%). They also had higher blastic colony than scores from BMT 
recipients (47 vs. 12 x 104/ml CFU-bl; p= 0.2). Results can be summarized that bone marrow stroma from 
patients receiving mobilized progenitor cells proliferates better than those receiving bone marrow grafts. 
It can be concluded that poor stromal layer and CD34+ cell proliferation following peripheral blood stem cell 
transplantation can be corrected by addition of basic Fibroblastic Growth Factor. 
X 
CHAPTERl 
Haematopoiesis is the process whereby cells of both myeloid and lymphoid lineages differentiate from a 
common stem cell into mature haematopoietic cells [8, 1 O]. It is characterized by the balanced interplay 
between haematopoietic progenitor cells, as well as molecules and cells that form part of the 
microenvironment. Cell adhesion molecules (CAMs) expressed on the cell surfaces of the 
haematopoietic progenitor cells bind to specific ligands on the stromal cells and the extracellular matrix 
(ECM) components. This interaction is important in that haematopoietic cells will be in contact with the 
growth factors produced by the stromal components. Heparan sulphate proteoglycans (HSPGs) are 
components of the extracellular matrix produced by stroma. They also play an important role in 
haematopoiesis because they bind to growth factors and present them to the haematopoietic cells within 
the microenvironment in an active form. The haematopoietic microenvironment is a highly organized 
structure where stem cells interact closely with the marrow stroma, and any alterations in the 
microenvironment may result in abnormal production of blood cells. 
faJ te\ls 
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Figure I. Schematic diagram of the haematopoietic microenvironment. Stem cells express cell adhesion molecules, which 
bind to their specific ligands in the extracellular matrix. Growth/actors are produced by stromal cells and they bind to their 
specific receptors on the stem cells. 
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1.1 Introduction 
The turnover of cells of the haematopoietic system in a man weighing 70 kg is estimated to be 1 trillion 
cells per day, and this includes 200 billion erythrocytes and 70 billion neutrophilic leukocytes [74,105]. 
In steady-state haematopoiesis, most progenitor cells reside in the bone marrow cavity and only a small 
percentage circulate in the peripheral blood. In the embryo, haematopoiesis starts between day 15 and 
18 in the blood island of the yolk sac (a location that supports only erythropoiesis). After 6 weeks, 
haematopoietic stem cell migrates via the blood stream to the liver and the spleen where myeloid 
differentiation begins [5 ,95]. During the 20th week of gestation, bone marrow haematopoiesis begins to 
occur, finally representing the whole system of blood cell production [98]. 
Within the bone marrow microenvironment, differentiation involves the haematopoietic stem cell, 
followed by long-term culture-initiating cell (LTC-IC), then colony forming unit-blast (CFU-bl) giving 
rise to the mixed colony forming unit-granulocyte-erythoid-macrophage-monocyte (CFU-GEMM) and 
finally the single lineage progenitors e.g., red cells, platelets, granulocytes (neutrophills, eosinophills), 
monocytes, and basophills . 
1.2 Haematopoietic Stem Cells 
Haematopoietic stem cells have three features : (1) a self-renewal capacity that is able to maintain a 
long-term supply of progenies, (2) a multilineage differentiation potential with the ability to clonally 
give rise to at least eight distinct cell lineages, (3) a proliferative potential that is responsible for the 
production of large numbers of mature blood cells . 
Stem cells are recognized by the expression of a glycoprotein called the cluster of differentiation (CD) 
34+ molecules. Clusters of differentiation (CD) are well-defined antigens that are recognized by specific 
monoclonal antibodies . This glycoprotein is expressed on the stem cell surface membranes; immature 
progenitor cells, as well as endothelial and fibroblastic progenitors . The CD34+ expression disappears as 
cells differentiate into late progenitors and mature blood cells [47,48,67,82]. 
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Cells that are included within the CD34+ population can further be defined by co-expression of 
additional markers that can discriminate between the primitive stem cells and lineage committed 
haematopoietic progenitor cells [69,95], e.g. primitive (non-committed) stem cells express CD34+CD38. 
while lineage committed cells express CD34+CD38+ [36,92]. 
The CD34+ cell population comprises 1-3% of bone marrow mononuclear cells, and 0.01-0.1% of 
peripheral blood mononuclear cells. This CD34+ cell population contains precursors for all 
lymphohaematopoietic lineages as shown by the finding that CD34+ cells purified from marrow can 
reconstitute haematopoiesis in humans [2 ,5,41 ,48,49]. 
The CD34+ selection is employed as a means to enrich stem cells in clinical transplantation protocols 
for multilineage engraftment and self-renewal [139]. The number of stem cells in CD34+ lineage 
negative (Lin·) fraction is 100-fold higher than the number of stem cells in CD34. Lin· fraction , so it is 
preferred to engraft CD34+ stem cells rather than CD34. cells [1 ,30] 
Higher CD34+ cell yields are obtained after positive selection from bone marrow aspiration performed 
during the day as opposed to late at night. It has been speculated that the temporal differences in 
physical properties related to cellular adhesiveness and distribution in the bone marrow space may be 
contributing factors. The CD34+ cells are used in gene therapy studies and as markers for early 
haematopoietic stem/progenitor cells [49]. 
1.3 Long-Term Culture-Initiating Cell 
The cell population that sustains long-term haematopoiesis when placed in a culture is called long-term 
culture initiating cell (LTC-IC). It represents a very primitive haematopoietic progenitor population, 
since it initiates and sustains committed myeloid progenitor growth for up to 12 weeks in long-term 
bone marrow cultures in humans. [29,54]. 
1.4 Colony Forming Unit-blasts 
The human marrow also contains a population of progenitor cells called colony-forming unit-blast 
(CFU-bl). They are self-renewing cells that occupy an early position in haematopoiesis. 
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The CFU-bl is assigned a new name, viz., pre-progenitor cells, (PPC) which represent a population of 
transit cells and precede the lineage-committed progenitor cells [37,63]. The relationship between LTC-
IC and CFU-bl is that CFU-bl is a descendant ofLTC-IC. 
1.4.1 Kinetics of Binding 
CFU-bl can be distinguished by their ability to bind to preformed stromal layers and to form blastic 
colonies in the absence of magnesium, calcium, and serum, suggesting that the stromal layer is 
responsible for the requirements of binding. This interaction does not appear to involve known cell 
adhesion molecules (CAMs), neither prevented by the presence of monoclonal antibodies reacting with 
known phosphatidylinositol (PI)-linked structures, nor affected during trypsinization [31 ,37,38]. 
Binding of progenitor cells to stromal layers is mediated by heparan sulphate proteoglycans secreted as 
part of the extracellular matrix by stromal cells. Adhered progenitors produce colonies of 
undifferentiated blast cells, which are a uniform population of cells with a high nuclear: cytoplasmic 
ratio, no cytoplasmic granules , and little sign of maturation [31 ,3 7]. 
1.5 Long-Term Bone Marrow Cultures 
Dexter and co-workers (61,76) first described long-term bone marrow cultures (LTBMC) in 1977. 
LTBMC reproduce the bone marrow microenvironment in vitro, thus allowing the identification of 
different components of the microenvironment and investigating their roles in haematopoiesis [88]. 
LTBMC can also be used to measure the combined injury to the haematopoietic stem cell and stromal 
cells and may reveal defects not apparent in short-term in vitro clonal assays. Colony forming unit-
granulocyte macrophage (CFU-GM) assays are employed to demonstrate that the proliferative capacity 
and differentiation have been retained in LTBMC [22,53 ,61]. 
When bone marrow cells are cultured in vitro, an adherent cell layer referred to as a stromal layer must 
first develop before haematopoietic cells are generated [22,53]. This layer is produced when foetal calf 
serum, horse serum, and hydrocortisone are added to the initial culture medium. However, when only 
foetal calf serum is added to the culture medium, only a fibroblastic layer is formed [19,79,98]. 
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The significant decrease in the total adherent cell number between weeks 8 and 9 is due to a significant 
decrease in fibroblasts , fat-containing cells and macrophages. The reason for this is that in older 
cultures, stromal layers form more three-dimensional bands, leading to a reduced cell contact to the 
glass surface and a greater tendency to become non-adherent [88]. 
1.6 Haematopoietic Microenvironment 
The haematopoietic microenvironment in adult humans serves as a site of normal haematopoiesis. It 
consists of the haematopoietic cells, stromal cell layer ( comprising endothelial cells, fat cells, 
fibroblasts, and macrophages), extracellular matrix (ECM), and growth factors . Haematopoietic cells 
seed within a stromal layer where they differentiate before being released into the culture supernatant as 
non-adherent cells [90]. If these haematopoietic cells were to be separated from stromal cells using a 
diffusion chamber on a layer of thin agar, they would die rapidly, implying a necessary intimate 
association with the stromal cells [22]. 
The heterogeneity of stromal cells within the LTBMC has complicated attempts to define the 
contribution of each component of the microenvironment in the regulation of haematopoiesis. 
Monoclonal antibodies (MoABs) are then used to provide a means of separating, characterising, 
identifying, and studying specific components in the heterogeneous system [77,80,88,90]. 
1.6.1 Stromal Layer Components 
A. Endothelial Cells 
Endothelial cells account for 10-20% of the adherent layer [3]. They form the morphologic and 
functional barriers between the vascular and haematopoietic compartments, where they exert controls 
over the cellular traffic between these two compartments, retaining the immature cells within the bone 
marrow [57]. The adhesive interactions between leukocytes and endothelial cells are central to homing 
of leukocytes to gastrointestinal tract and other lymph nodes, and are also likely to play a role in 
homing ofhaematopoietic cells [19,94]. 
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B. Fat Cells 
Fat cells occupy 5-10% of the adherent layer and are identified by their size, small nucleus, vacuolar 
cytoplasm and their positivity for the lipid-specific dye (Oil-0-Red). The appearance of fat cells in 
LTBMC depends upon the addition of hydrocortisone (HC) to the culture media [l] and they typically 
develop within four weeks in an adherent layer. The number of fat cells is increased with time in culture 
and this increase is associated with enlargement of their globules [3, 19]. 
C. Fibroblasts 
The fibroblasts represent a major component (60-70%) of the adherent layer. They are elongated, non-
phagocytic, self-replicating cells known to be plastic adherent. The clonogenic progenitors responsible 
for fibroblastic colony formation are called colony forming unit- fibroblasts (CFU-Fs) [19,94]. 
Fibroblasts have a regulatory role in the differentiation and proliferation of haematopoietic cells in 
vitro, by producing paracrine and autocrine growth factors that can affect their own replication as well 
as that of nearby macrophages , endothelial cells and other cells of the bone marrow [19,40]. 
D. Macrophages 
Macrophages account for 10-20% of the adherent cells of the human bone marrow stroma, and 70-90% 
of the murine bone marrow stroma. They play an important role in the regulation of haematopoiesis by 
producing cytokines such as IL-la, IL-1~ and GM-CSF [3]. These growth factors interact with 
haematopoietic cells directly or through specific cell surface receptors, which play a central role in the 
regulation of flow ofhaematopoietic progenitors into a required cell compartment [19,36,94]. 
The above-mentioned stromal layer secretes ECM components that are organized into a fibrillar 
network, surrounding the haematopoietic cells. The ECM components include collagen, fibronectin , 
haemonectin, heparan sulphate proteoglycans (HSPGs) and laminin, [3 ,1 9,94]. 
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1.6.2 Extracellular Matrix Components 
Fibronectin is a 450 kDa glycoprotein with a disulphide bond near the carboxy terminus. This molecule 
is responsible for mediating cell attachments, adhesion to collagen and laminin. The latter is a 900 kDa 
glycoprotein with three chains arranged in a cross-shaped tertiary structure, stabilized by disulphide 
bonds. Haemonectin is a 60 kDa glycoprotein that has only been identified in the marrow and believed 
to bind maturing granulocytes [20]. 
Heparan sulphate proteoglycans (HSPGs) are high molecular weight molecules in which sulphated 
glycosaminoglycans (GAGs) are covalently attached to a core protein [19,94]. GAGs are important 
components of the ECM and are also important in the regulation of haematopoiesis by binding and 
presenting cytokines to the haematopoietic cells in a more highly active form [87,96]. 
Heparan sulphates (HS) associated with bone marrow stromal cells participate in the adhesion of 
primitive haematopoietic cells to stroma, but functionally they vary due to differences in chemical 
structure [3 ,16,87]. Heparan sulphates are required for the maintenance ofLTC-IC, while heparin, 
(a highly sulphated vers ion of HS) directly activates growth factor receptor [96]. 
There are two classes of molecules that contribute to the maintenance of haematopoiesis : the growth 
factors , which have a well-documented capacity to stimulate survival, growth and development of 
primitive stem cells in vitro and cell adhesion molecules, which support the physical association of cells 
with the haematopoietic microenvironment. 
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1. 7 Growth Factors 
I 
J 
Figure 1. Schematic view of the action of growth factors on the haematopoietic cells. Binding of growth factor to 
its specific receptor on the cell surface causes alterations in the intracellular domain of the receptor. This leads 
to the release of specific second messengers by activating one or other specific enzymes in the signal 
transduction pathway. 
Growth factors are a group of proteins that have potent biological activities, and are released by many 
cell types: the stromal cells, cells that make up the immune system, thymus, spleen, lymph nodes and 
other lymph organs. Growth factors are released at the site of tissue damage and participate in the 
reconstruction of cellular organization following an infection. Activation of cells is mediated by the 
interaction of growth factors with specific receptors expressed on the cell membrane surfaces, which 
then trigger intracellular events leading to the cytokine action [99]. 
The haematopoietic growth factor receptors belong to two major groups oftransmembrane proteins: the 
tyrosine kinase receptor and the haemapoietin receptor family. The tyrosine kinase receptors have an 
extracellular ligand-binding domain with one or more protein molecules including immunoglobulin 
(Ig)-like, fibronectin type ill and epidermal growth factor like domains. 
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This family includes stem cell factor (SCF), which has little colony-forming effect when used alone, but 
stimulates the in vitro proliferation of both myeloid and lymphoid haematopoietic progenitors when 
combined with other cytokines like erythropoeitin (Epo ), interleukin-3 (IL-3), and granulocyte-
macrophage colony stimulating factor (GM-CSF) [34,68]. 
Growth factors can be categorized into three main groups: (1) growth factors such as IL-1 and IL-2, 
which influence the growth and differentiation of B- or T-lymphocytes or their precursors; (2) growth 
factors such as IL-3, IL-6, SCF, which directly stimulate multi potent cells in terms of proliferation and 
development of colonies in vitro; (3) the colony stimulating factors (CSFs) such as GM-, G-, M-CSF, 
which influence the growth and development of myeloid progenitor cells . All these groups can further 
be divided into effector categories, e.g., survival , proliferation, and differentiation [26]. 
1. 7 .1 Cell Survival 
Bone marrow cells removed from the body will only survive if they are cultured in the presence of 
growth factors . Haematopoietic cells depending on a specific growth factor for their survival need to be 
in the proximity of a stromal cell or matrix environment that can produce that growth factor or require 
the external addition of that specific growth factor into the culture medium. Cells outside the vicinity of 
such an environment will undergo a process of apoptosis. If the appropriate growth factor is present, 
they will survive and if the concentration of the growth factor is effective, they will proliferate and 
differentiate to produce more mature end cells [27]. 
1.7.2 Cell Differentiation 
An initial phase when haematopoietic progenitor cells respond to an appropriate stimulus and develop 
into mature committed cells is called differentiation. Growth factors stimulate the stem cells to undergo 
differentiation, producing more developmentally restricted cells . 
1.7.3 Cell Proliferation 
The process when haematopoietic cells increase in number is called proliferation. Survival and 
proliferation are linked to the concentration of growth factors and the number of receptors they 
occupied at a given time. 
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This is demonstrated by the observation that when haematopoietic cells are cultured in media containing 
low concentration of a growth factor, they survive but do not proliferate. The cells will only start 
proliferating when the growth factor concentration is increased [27]. 
1.8 Basic Fibroblast Growth Factors 
Fibroblast growth factors (FGFs), epidermal growth factor (EGF), and transforming growth factor-f3 
(TGF-~) are produced by the stroma. FGFs belong to a complex family of mostly mitogenic proteins 
that share varying degrees of amino acid homology, but bind different receptors with variable affinity 
and gain extracellular exposure via different processes. They include factors like acidic (FGF-1), basic 
(FGF-2) and keratinocyte growth factor (KGF or FGF-7). A basic type of bFGF, which is used in this 
study has an isoelectric point (pl) of greater than 9, a molecular weight of 18500 Dalton [33,75,79]. 
1.8.1 Sources of bFGF 
Basic FGF is isolated from bone, kidney, placenta, prostate, retina, brain, pituitary gland, and adrenal 
gland. It is synthesized by cultured normal and malignant cells and produced by human bone marrow 
cells. Both platelets and megakaryocytes might serve as its source in the peripheral blood and bone 
marrow [18,34,76]. 
1.8.2. Location of bFGF 
Intracellular bFGF is localized in the cytoplasm, nucleus and nucleoli of many cell types while 
extracellular bFGF is deposited in bone marrow extracellular matrix as a complex with heparan sulphate 
proteoglycan (HSPGs) [15 ,17]. Basic FGF associated with HS proteoglycan constitutes a reservoir for 
this growth factor, protecting it from proteolytic degradation and therefore allowing it to mediate long-
term biologic effects [3,33 ,103]. 
These bFGF-HS proteoglycan complexes were thought to be released in a biologically active form by 
incubation with exogenous inositol specific phospholipase C (PLC) or serine protease (plasmin) [15-
17,40]. It was later noted that GPI-bFGF complexes are released from bone marrow cultures by 
endogenous glycophosphatidylinositol-phospholipase D (GPI-PLD) [16]. 
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The mechanism of the release is thought to involve GPI-PLD, but not PLC because the released variant 
surface glycoprotein did not reveal an epitope called the cross-reacting determinant, which is exposed 
by PLC-catalyzed GPI anchor cleavage. 
Glycosylphosphotidylinositol phospholipase D (GPI-PLD) not only regulates action of haematopoietic 
growth factors, but also mediate the cell-cell interactions in the bone marrow microenvironment [16]. 
1.8.2. Functions of bFGF 
Basic FGF is a multifunctional growth factor that is involved in angiogenesis, embryogenesis, wound 
repair, and also haematopoiesis [15,35]. It accelerates the formation of a primary stromal layer 
following inoculation of newly harvested bone marrow cells into dishes . It is mitogenic for bone 
marrow stromal cells, because they attain high densities, lose their contact inhibition and grow in 
multilayered sheets in its presence [15, 17]. 
Low concentrations of bFGF enhance myelopoiesis in LTBMC and result in an increase in the number 
of non-adherent and adherent layer derived progenitor cells [42]. Basic FGF also affects human 
megakaryocytes by directly promoting megakaryocytic progenitor cell proliferation and stimulating 
bone marrow accessory cells to release growth factors with the megakaryocytic colony stimulating 
activity, such as IL-3 and GM-CSF [17,34]. 
It further augments the proliferation of progenitor cells when added in conjunction with other growth 
factors and counteracts the suppressive effects of transforming growth factor (TGF)-~ [64]. Basic FGF 
and SCF are synergistic in regulating stem cell proliferation and differentiation in the bone marrow 
[16,34]. 
1.9. Cell Adhesion Molecules 
The second classes of molecules that contribute to the maintenance of haematopoiesis are cell adhesion 
molecules (CAMs). They are present on the surface membranes of progenitor cells and bind to their 
ligands on the stromal cells or the extracellular matrix components. 
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Restriction of early haematopoietic cell development and haematopoietic tissue involves expression of 
these CAMs [5 ,24,25,39]. Cell adhesion molecules belong to a six-structural family: integrins, selectins, 
immunoglobulin (Ig)-like molecules, CD44 molecule, cadherins , and sialomucin. Integrins are a large 
group of CAMs and are given this name because of their ability to integrate the intracellular 
cytoskeleton with extracellular matrix. Integrins are involved in cell migration and tissue organization 
during differentiation and inflammation, respectively, and mediate cell-cell and cell-ECM interactions 
[89]. 
Specific adhesion receptors on progenitor cells that mediate cell-ECM interaction have been described, 
viz., f3 1-integrin adhesion molecule, very late antigen-4 (VLA-4), VLA-5 and VLA-6 and the receptor 
for hyaluronic acid (HA), CD44. Receptors like CD31 /platelet endothelial-cell adhesion molecule-I 
(PECAM-1 ), the f3 i- integrin intracellular adhesion molecule-1 , and also VLA-4 mediate cell-cell 
interactions [5 ,24,25 ,94]. 
The second groups of CAMs are selectins, which are divided into the L- and the P-selectins. The L-
selectins are expressed on mature myeloid cells (e.g., neutrophils, eosinophils and monocytes) whilst a 
proportion of bone marrow endothelial cells express the P-selectins. Both selectins are involved in 
leukocyte adhesion to vascular epithelium and platelets [16,89]. 
The third group . of CAMs are immunoglobulin (lg)-like molecules that are expressed by human 
haematopoietic progenitor cells including LFA-3 (CD58), ICAM-1 (CD54) and Thy-1, while ICAM-1 
and Thy-1 are also expressed by marrow stromal cells [l 00]. 
The fourth groups of CAMs are CD44, which are major cell surface receptors for hyaluronic acid and 
exhibit multiple activation states. Anti-CD44 antibodies identify primitive human haematopoietic 
progenitor cells and marrow stromal cells [l 00]. 
Interactions between progenitor cells , stromal cells and extracellular matrix (ECM) organize the cells to 
be in contact with growth factors needed for their proliferation and differentiation. Interaction of 
progenitor cells with endothelial cells is important for migration and homing of progenitors cells to the 
bone marrow. This involves tethering and rolling of haematopoietic progenitor cells along the 
endothelium. 
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Growth factors located on the endothelial surface or bound to proteoglycans in the endothelial 
extracellular matrix, activate the p1 and Pz-integrins on the rolling haematopoietic progenitor cells, 
leading to firm adhesion to lg-like receptors on the endothelial cells. This process is then followed by 
the transendothelial migration and anchoring of the progenitor cells in the bone marrow 
microenvironment [20,24,89]. 
1.10. Haematological Malignancies 
Patients who participated in this study presented with the following haematological malignancies: 
chronic myeloid leukaemia (CML), acute myeloid leukaemia (AML), myelodysplastic syndromes 
(MDS), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukaemia (ALL), and severe aplastic 
anaemia (SAA). 
1.10.1. Leukaemia 
Leukaemia is a haematological clonal disorder, which is characterized by the uncontrolled proliferation 
of the haematopoietic progenitor cells, leading to accumulation of immature cells in the bone marrow or 
peripheral blood. Myeloid type of leukaemia arises from a transformation of haematopoietic stem cells 
accompanied by a reduced normal haematopoiesis . This change is brought about by the release of 
cytokines such as TNF-cx. from leukaemia cells [59 ,61 ]. Stromal compartments in leukaemia are not 
derived from the malignant clone and are sensitive to and traumatized by cryopreservation [59,69]. 
There are two types of myeloid leukaemia: the chronic myeloid leukaemia and acute myeloid 
leukaemia. 
A. Acute Myeloid Leukaemia 
Acute myeloid leukaemia (AML) is a malignant clonal disorder characterized by expansion of 
immature myeloid cells that are unable to differentiate fully, leading to accumulation of immature cells 
in the marrow or the blood. If it is left untreated, AML is more severe than CML because with AML, 
the survival period from diagnosis is only a few months, while with CML the period lasts for up to four 
years [50,59]. 
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B. Chronic Myeloid Leukaemia 
Chronic myeloid leukaemia (CML) is characterized by a clone that have the Philadelphia (Ph) 
chromosome, which results from the reciprocal translocation between chromosomes 9 and 22. This 
translocation leads to a fusion of the BCR and the c-ABL genes and the creation of a functional 
oncogene. CML develops in two phases: An initial chronic phase, which typically extends for years and 
a later blastic crisis, which is usually untreatable and rapidly fatal. Leukaemia cells present in patients 
with chronic phase CML differentiate normally. Other feature of CML is the presumed origin of 
leukaemia cells in a stem cell with lymphoid as well as myeloid differentiation potential [32,59]. 
1.10.2 Myelodysplastic Syndromes 
Myelodysplastic syndromes (MDS) are characterized by the ineffective proliferation of cells from an 
abnormal stem cell leading to abnormalities of maturation and function of blood cells . 
In the French-American-British (FAB) classification, they are categorized into refractory anaemia (RA), 
RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in transformation (RAEB-
t), and chronic myelomonocytic leukaemia (CMMoL). About 20-40% of MDS transform into acute 
leukaemia phase (post MDS AML) [56,65]. 
1.11 Bone Marrow Transplantation 
Bone marrow transplantation (BMT) involves the elimination ofan individual's bone marrow stem cells 
and all the cells derived from them including haematopoietic, lymphoid and macrophage systems. The 
eliminated cells are replaced with bone marrow stem cells either from another individual or with a 
previously harvested portion of the individual's own marrow. Since its introduction in the early 1970s, 
BMT has gained wide acceptance [21 ,72] and can either be allogeneic or autologous transplantation. 
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1.11.1 Allogeneic BMT 
Allogeneic BMT is when bone marrow is transferred between siblings or I-ILA-matched individuals and 
is an effective therapeutic modality for the management of CML. Allogeneic BMT is associated with a 
high incidence of graft versus host disease (GVHD), which is mediated by T-lymphocytes. 
Relapse of diseases after allogeneic BMT remains a major cause of treatment failure with a very poor 
prognosis . Minority of relapsed patients is cured with a second BMT, which results in significant 
morbidity and poor survival rates [19]. 
1.11.2 Autologous BMT 
Autologous BMT is when bone marrow is collected from one individual and then reinfused after 
myeloablative conditioning. Conditioning regimens for autologous transplantation do not need to be 
immunosuppressive, since there is greater flexibility in designing protocols, which can provide maximal 
intensive therapy to eradicate the leukaemia [64]. 
The most commonly used conditioning regimen for autografting in patients with advanced acute 
leukaemia is a combination of cyclophosphamide (CY) and total body irradiation (TBI). Another 
combination, viz., melphalan and single fraction TBI, is used extensively in the treatment of acute 
leukaemia in the first remission [21 ,64]. 
Haematopoietic recovery for patients receiving autologous BMT is slower compared to recovery of 
patients accepting allogeneic BMT. This is most often because autologous patients who received 
previous chemotherapy have impaired stem cell quality, which further decreases the supportive effect of 
the endogenous stroma component [44]. 
1.12 Peripheral Blood Stem Cell Transplantation 
During the past 5 years, cytokine-mobilized (G-CSF) peripheral blood stem cells (PBSC) have replaced 
bone marrow as the most frequently used source of haematopoietic progenitors for autologous and 
allogeneic transplantation. For early engraftment after transplantation, cytokines that facilitated 
haematopoiesis were used. However, some patients show graft failure and die of infectious 
comp! ications [ 12,23 ,46,97]. 
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PBS Cs represent a unique population of bone marrow progenitor/stem cells and are released from the 
bone marrow to reseed damaged marrow spaces. PBSCs circulate in peripheral blood of normal 
individuals at concentration of 0.1-0.01 of the amount found in the bone marrow. They have been 
characterized using in vitro cultures and the presence of all haematopoietic clonal cells had been 
demonstrated. The CD34+ cells found in PBSCs are similar to those found in the bone marrow, 
suggesting that they have the ability to repopulate the haematopoietic system of the irradiated recipient 
[12,66,97]. 
PBSCs are more advantageous than bone marrow stem cells because of their lower sensitivity to 
radiation, increased frequency of cells in the S-phase, delayed logarithmic growth, and increased 
seeding efficiency [66]. Other advantages of PBSCs over bone marrow cells are their rapidity of 
engraftment (which diminishes certain transfusion requirements and may also reduce the risk of serious 
infection) and those stem cells can be collected in the outpatient setting with minimal morbidity [46]. 
The use of PBSCs for allogeneic transplantation could result in similar benefits. Over the past few 
years, the clinical use of PBS Cs instead of bone marrow was associated with a significant improvement 
of the haematological recovery after myeloablative chemoradiotherapy in patients with lymphoma, 
myeloma, and other tumour [28]. Recovery after transplantation includes processes like homing of the 
infused stem cells into appropriate microenvironment, expansion of their early progenitor cells and 
differentiation into mature blood cells [52]. 
1.13 Abnormalities after Transplantation 
Myeloablative therapy and transplantation cause abnormalities of the stroma. These abnormalities were 
demonstrated by an incomplete formation of the stromal layer in the bone marrow obtained from 
patients undergoing allogeneic BMT and autologous peripheral blood progenitor cell transplantation. 
These abnormalities were still evident even after six years after transplantation [72,73,80]. 
There was a selective defect in the ability of bone marrow stroma from patients with AML to support 
maturation of normal early, uncommitted haematopoietic stem cells (CD34+CD38), whilst the ability to 
support the committed (CD34+CD38l cells was not affected [92]. 
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BM stromal cultures derived from patients with CML also displayed functional defects, as indicated by 
a decreased supporting capacity to normal haematopoiesis . Recently, it had been demonstrated that, like 
in AML, this dysfunction might be due to the presence of malignant macrophages in the CML-derived 
stromal cultures [73 ,80]. 
Hydroxyurea was demonstrated not to have an effect on stroma function , but when combined with the 
conditioning treatment before transplantation, it led to defective in vitro development of stroma cells 
from bone marrow. This suggested that it might have been the conditioning therapy that was responsible 
for the severe deficiencies in stromal growth and supportive ability in cultures from transplanted 
patients [80]. 
There was reduced adhesion of stem cells onto leukaemia bone marrow stroma, which led to stem cell 
loss and decreased marrow recovery [69,70]. Reduction in the clonogenic potential of stroma adherent 
CD34+ cells suggested that haematopoiesis after transplantation was maintained by reduced numbers of 
clones [70, 72,80]. 
Certain alterations that were observed in AML patients included a reduced number of fibroblast 
progenitors (CFU-F) as well as decreased density macrophages and adipocytes [60]. Functional 
abnormalities were observed in both AML and CML patients because of their inability to possess 
haematopoietic supportive capacity [72]. 
AIMS 
It has been described that following transplantation, defects in the function of the stroma develop. These 
defects are associated with decreased adhesion of stem cells to leukaemia bone marrow stroma, which 
in turn, lead to reduced clonogenic potential of the stroma-adherent CD34+ cells . All these 
abnormalities alter the process of normal haematopoiesis. Basic fibrobl ast growth factor (bFGF) is used 
in this study in attempt to restore this defective haematopoiesis that follow stem cell transplantation. 
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OBJECTIVES 
To evaluate the in vitro effects of basic fibroblast growth factor on the: 
• Damaged stroma subsequent to transplantation. 
• Proliferative capacity of stromal cells after transplantation. 
• Stromal supportive capacity for the growth of normal blastic colonies following transplantation. 
• Clonogenic potential of stroma-adherent cells after transplantation. 
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CHAPTER2 
A comparison of marrow stromal proliferative activity in samples drawn from patients who 
had undergone bone marrow versus peripheral blood stem cells. 
Objectives: 
• To introduce the importance of bone marrow stroma in haematopoiesis and that any stromal 
damage may result in inadequate stem cell reserves . 
• To determine whether following PBSCs graft infusion, correction of the described 
abnormalities subsequent to BMT could be detected, given that more mononuclear cells, 
CFU-GM, and presumably more stem cells were infused after myeloablative conditioning. 
• To compare the haematopoietic recovery between patients receiving peripheral blood stem 
cells (PBSCs) and those patients undergoing bone marrow (BM) transplantation. 
2.1 Introduction 
Myeloablative therapy followed by allogeneic or autologous bone marrow or stem cell 
transplantation became standard in a variety of haematological malignancies [70,72]. Usually, 
recovery of the bone marrow and peripheral blood values ensue within 3-5 weeks of transplantation. 
However, engraftment in a proportion of patients, may be delayed, whereas in other patients a 
significant drop in blood parameters may follow infection [6]. 
Exposure of animals to ionising energy resulted in impairment of the haematopoietic 
microenvironment and alterations in the bone marrow precursor [29], suggesting persistent reduction 
in the progenitor cell pool. Using the blastic colony assay, Novitzky et al [70] showed that this was 
due to significant reductions in the earlier stroma-adherent precursors, while haematopoiesis was 
maintained through expansion of the committed progeny. It was deduced that despite normalization 
of blood parameters, there had not been normalization of the stroma-adherent precursors, thus 
pointing out that the number of progenitors in the graft may need to be maximized. 
Allogeneic cytokine-mobilized blood stem cell transplantation has been associated with faster 
recovery than bone marrow transplantation . This distinction is readily explained by larger proportion 
of progenitor cell numbers present in the graft of the stem cells . 
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Table 2.1. Comparison of clinical and demographic data of patients receiving PBSC or BM 
grafts 
BMT (n = 9) PBSC (n = 13) P-value 
Median Age (range) 26 (14-39} 41 (23-57) 0.03 
Gender Male/Female 4/5 3/10 >0.05 
Median MNC x 108/kg, (range) 0.9 (0.79-1.35) 7.3 (3 .76-13 .57) 0.00003 
CFU-GM X 104/kg 5 (3 .5-11) 38 .8 (3 .1-379) 0.05 
Haemoglobin (Hb) g/dl 12.7 (11-13 .5) 12.5 (10 .9-14 .2) >0 .05 
Leukocytes x 109 /I 5.3 (3 .6-8.7) 7.1 (3 .0-10.2) >0.05 
Polymorphs x 109/1 2.36 (1.8-6 .6) 4.2 (2 .2-8 .3) >0.05 
Platelets x 109 /I 183 (163-335) 211 (166-311) >0.05 
Patients receiving mobilized PBSC grafts were older and studied at a shorter period following 
transplantation. A significant difference in MNC and CFU-GMs infusion between PBSCT and EMT 
patients is shown. Significance level was set at <O. 05. 
2.2 Methods 
Twenty-two patients who had received allogeneic stem cell grafts for haematological malignancies 
were studied. This is a retrospective analysis that included sequential patients who received BMT 
until 1998 and cytokine-mobilized allogeneic PBSCT thereafter. Thirteen patients received PBSC 
grafts while nine patients were undergoing BMT. The median age was 41 (range 23-5 7) for those 
receiving PBSC and 26 (range 14-39) for BMT patients. The control population was drawn from 
haematological normal individuals undergoing stemotomy for cardiac surgery under general 
anaesthesia. The University of Cape Town Ethics Committee approved this study and all patients 
gave informed consent for bone marrow collections. 
Bone marrow aspirates were diluted with a-Minimum Essential Medium (a-MEM) (Gibco, Life 
Technologies, and UK). Aspirates were layered onto 4 ml Ficoll-Histopaque with a density gradient 
of 1,077 g/ml (Sigma, St. Louis, and MO) and centrifuged at 400 g for 30 minutes to remove 
erythrocytes and granulocytes. 
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Light density population [containing mononuclear cells (MNCs)] was collected from the intetface 
layer, pooled and washed three times with a-MEM to remove Ficoll-Histopaque which is known to 
be toxic to the cells . MN Cs were resuspended in 10 ml of a-MEM and an aliquot was counted on a 
particle counter (Coulter Electronics, USA). MNCs sample was divided into two aliquots, one to 
establish bone marrow stromal layers and the other for the selection of CD34+ cells . 
2.2.1 Stromal Assay 
This assay was petformed to measure the proliferative capacity of stromal layer components. A 
comparison in stromal proliferation between patients receiving PBSC and those undergoing BMT is 
also evaluated . MNCs were cultured at a concentration of 0.5 x 106/ml in 3 5 mm petri dishes (Bibby, 
UK) in a-MEM supplemented with 15% of each foetal calf serum (FCS) and horse serum (Gibco), 
2 x 1-6 Mol hydrocortisone (HC), 0.3 µg/ml gentamicin. Stromal cultures were incubated at 37° C in 
5% CO2 and the media changed weekly throughout the culture duration. Stromal confluence was 
quantitated by placing culture dishes on a grid containing 1 mm squares and scoring the number of 
squares occupied by stromal layers as a percentage area covered . 
2.2.2 Progenitor Cell Selection 
This procedure was implemented to select haematopoietic progenitors that express the CD34+ 
antigen on their cell sutface membranes. The second aliquot of bone marrow MN Cs was incubated 
in 150 mm petri dish (Bibby, UK) for 2 hours at 3 7°C in 5% CO2 to remove monocytes . Non-
adhesive population of cells from dishes were lymphocyte-depleted by addition of Campath IM 
(6 .25 mg/ml ; 0 .01 ml antibody/5 x 106 cells/ml) in the presence of30% fresh AB serum as a source 
of complement and then incubated in 150 mm petri dish for 50 minutes at the same conditions as 
above. 
The lymphocyte and monocyte poor cell population was suspended in cold (4°C) PBS and exposed 
fo r 30 minutes to paramagnetic beads covalently bound to anti-CD34 monoclonal antibody (Dynal, 
Olso) on an apparatus that provides both the tilting and rotation . Rosetted cells were recovered with 
a magnetic particle concentrator (MPC), and then released from beads by incubation with a 
"Detachabead" (polyclonal murine immunoglobulin : Dynal , Oslo) . Selected CD34+ cells were 
resuspended in 1 ml of2% AB serum/PBS solution and a CD34+ count petformed manually using a 
Neubauer counting chamber and adjusted to a concentration of 1 x 104/ml. 
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2.2.3 Colony Forming Unit-blast (CFU-bl) Assay 
This assay was performed in order to compare the stromal supportive capacity and the clonogenic 
potential of selected CD34+ cells between patients receiving BM or PBSC grafts . Selected 1 x 104 
CD34+ cells were suspended in 1 ml of a-MEM supplemented with 15% FCS, layered in duplicate 
onto preformed stroma in cross-culture studies and incubated for 2 hours to allow optimal 
adherence. The stroma non-adherent cells were removed by standard washing with Iscove's 
Modified Dulbecco's Medium (IMDM) and cultured in colony forming unit-granulocyte 
macrophage (CFU-GM) assay. 
Stroma-adhered cells were covered with 0.3% agar, a-MEM supplemented with 30% FCS, and were 
incubated at 3 7°C in 5% CO2 for 5 days . Aggregates containing more than 20 cells were counted as 
blastic colonies on day 6 using an inverted microscope. When stroma was not confluent, CFU-bl 
results were expressed by multiplying the colony number obtained by 100 and divided by the 
percentage surface area covered (CFU-bl x 100/% surface covered). 
2.2.4 Colony Forming Unit-Granulocyte Macrophage Assay 
This assay was carried out to measure the clonogenic and proliferative capacity of selected CD34+ 
cells between patients receiving either BM or PBSC grafts . Stroma non-adherent CD34+ cells were 
cultured in the presence of 10 ng/ml GM-CSF, 30% FCS, and 0.3% agar. They were incubated for 
14 days at 37°C in 5% CO2. For permanent recording, CFU-GM cultures were fixed with 0.25% 
glutarylaldehyde for 7 minutes and then floated in weighing boats containing water. The pellicles 
were mounted on the slide and stained with May-Gri.inwald-Giemsa (MGG). Using an inverted 
microscope, aggregates of more than 40 cells were counted as CFU-GMs. 
2.3 Results 
Patients ' demographic data and blood parameters at study are given in Table 2.1. The median time 
from transplantation to the investigation of the marrow populations was 12 months (range 6-12). In 
the PBSC group, grafts contained a median of 1.2 (range 0.7-2.2) CD3 4+ cells/kg, while similar data 
for patients undergoing BMT was not available. 
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Table 2.2. Comparison in stromal confluence, blastic colony, and non-adherent cell results 











































Data represents results of the percentage area covered by stroma, blastic colony and CFU-GM 
between PBSCT and EMT patients. The last column gives the ratio between CFU-bl and CFU-GM 
## denotes significance difference between patient and control population, while * * indicates 
significant values between both stem cell sources. 
2.3.1 Appearance of Bone Marrow Stroma 
Quantitation of stromal monolayers confluence was determined at 4-6 weeks from initiation of 
cultures. The median area covered by stroma in normal individuals was 98% (range 76-100) while 
the median area of the dish covered from both stem cell sources was 47 .5% (range 0-80%). Both 
stem cell sources showed significantly less growth compared to the median area covered by cells 
from normal individuals (p= 0.0001 ; Table 2.2). 
23 
2.3.2 CFU-bl and CFU-GM 
Within the transplant group, CD34+ cells from patients who had received mobilized PBSC grafts 
cultured on normal stroma had higher CFU-bl scores than those originating from BMT recipients, 
but the differences were not significant (p = 0.2). Both PBSC and BMT CD34+ cells generated fewer 
CFU-bl than selected normal cells (12 and 47 vs. 98%; p=0 .003 ; Table 2.2). 
In cross-culture experiments, stroma from patients who had recovered from both sources of stem 
cell transplantation supported less well normal stroma-adherent CD34+ cells than did control stromal 
layers (21.5 vs . 97 .5 CFU-bl ; p = 0.0003). However, when control 1 x 104 CD34+ cells were layered 
onto stroma from patients receiving PBSC or BM, significantly more colonies were scored on 
stromal layers originating from patients who received PBSCT (median 39, range 2-121) than those 
who received BMT (median 5, range 0-59; p = 0.03). The median colony numbers from both 
sources of patients was 29.5 (range 2-133) and these scores were significantly lower than blastic 
colonies from normal individuals (median 98 ; p=0 .03 ; Table 2.2). 
Stroma non-adherent CD34+ cells eluted after a 2-hour incubation from patients' stromal layers and 
cultured in CFU-GM assay led to median values of colonies that were not significantly different 
from the control group . However, the ratio of CFU-bl/CFU-GM within the CD34+ population 
confirmed a significant reduction in the proliferation of CFU-bl that was compensated by a larger 
proportion of CFU-GM and normalization of the blood values (Table 2.1). 
In summary, despite similar conditioning and adequate recovery of blood parameters, individuals 
receiving PBSC grafts formed significantly more extensive stroma and when corrected for surface 
area, they supported greater numbers of normal CFU-bl than those receiving BM grafts . The 
normalization of blood parameters may have occurred from significant amplification of the 
committed (stroma non-adherent) progenitors monitored using the CFU-GM assay. 
2.4 Discussion 
Using stroma dependent assays, Novitzky et al [70], observed that following autologous or 
allogeneic BMT, a derangement in the proliferation and function of the bone marrow stroma and of 
the selected CD34+ bone marrow progenitors was noted. They documented a reduction in the 
clonogenic potential of the CD34+ population, which does not recover even 8 years after BMT [70]. 
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In the current study, we compare the results of patients who had received two different sources of 
stem cell transplantation . The results show that cells derived from patients receiving cytokine-
mobilized PBSC transplants express a modest recovery in CFU-bl and a significant expansion in the 
area of the dish covered by marrow stromal layers. Normalization of the blood values appear to be 
associated with active proliferation of the more committed population of stroma-adherent cells, as 
performed in CFU-GM assay (Table 2.1 ). 
Recovery in the stroma is associated with greater proliferation of normal CD34+ stroma-adherent 
precursors leading to higher CFU-bl numbers . These improvements are only noted when normal 
sources of stem cells are used, not with stem cells from patients who had received transplantation. 
Faster recovery of blood parameters with PBSC grafts may be related to the presence of larger 
numbers of committed precursors that rapidly differentiate into functional elements, while the most 
primitive self-replicating ancestors that develop slowly may be released in more limited proportions. 
As these studies were performed at a median of 6 months following infusion of the graft, recovery of 
the progenitor cell population might have not been complete. This is unlikely as no difference 
between those tested at 6 or 12 months post-transplantation was noted [72]. 
To enhance the haematopoietic recovery after stem cell transplantation, a number of strategies to 
improve mobilization of CD34+ cells to the blood have been attempted . It is of particular note that 
large numbers of endothelial [86], lymphoid, monocytoid and other undefined populations together 
with haematopoietic precursors may also be harvested . The cytokine-mobilized PBSC harvest may 
also be enriched for elements that are critical for the recovery of the bone marrow 
microenvironment. Investigations to demonstrate these populations were not performed in this 
study. 
In a similar way, PBSCs have higher numbers of CFU-GM. Furthermore, the addition of stromal 
cells in the foetal sheep model showed that donors' stromal elements repopulated marrow spaces 
and this facilitated donor stem cell engraftment. A direct benefit in survival of patients receiving 
PBSC grafts, where cytokine-mobilized blood cells that allowed a faster engraftment were used, has 
not been documented [86]. 
Even though blood counts in both groups normalized, two issues are still of practical relevance. 
Firstly, despite increases in the number of CD34+ cells in the graft above a threshold of 5 x 106 
cells/kg, the rate of engraftment has not been shortened beyond 9 days from transplantation and this 
delay may be directly dependent on the integrity of the stroma. 
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Secondly, there is evidence that the transplantation procedure may compromise the longevity of the 
haematopoietic stem cells, as assessed by re-transplantation assays in animals or shortened telomeric 
sequences in leukocytes from patients receiving allogeneic transplants as compared to their donors 
[51]. 
2.5 Conclusion 
In the current study we show that the bone marrow stroma from patients receiving mobilized 
progenitor cells proliferated better than patients receiving bone marrow grafts . We postulate that 
elements that are important for the integrity of the bone marrow microenvironment may also be 
released into the circulation . 
It would be of importance to establish if a healthier microenvironment may lead to improvement in 
the recovery of the transplanted stem cell population . This may be of particular significance to 
patients who are receiving repetitive courses of chemotherapy that are damaging their 
haematopoietic and mesenchymal cell progenitors . 
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CHAPTER3 
The effects of basic Growth Factor on the clonogenic potential of normal CD34+ cells. 
Objectives: 
• To establish ifbFGF has a direct clonogenic effect on selected CD 34+ cells . 
• To establish the effects of low and high concentrations of bFGF with other growth factors on 
CD34+ cells. 
3.1 Introduction 
Cytokines are a group of proteins that have potent biological activities . Activation of cells by 
cytokines is mediated by an interaction with specific receptors expressed on the cell membrane 
surfaces, thereby triggering intracellular events leading to a specific action. Most cytokines have 
pleiotropic effects, meaning that in addition to the stimulation of cellular proliferation, they also 
mediate a wide range of other activities e.g., wound healing. Cytokines induce cell proliferation by 
affecting the expression of genes involved in normal growth control pathways. 
Pleiotropic cytokines such as interleukin (IL)-3 and stem cell factor (SCF) stimulate cells of the 
myeloid lineage. Activity of cells is mediated by interaction of cytokines with specific receptors 
expressed on the surfaces of target cells, thereby triggering intracellular events leading to an 
observed cytokine action [99]. These cytokines can be grouped into early-acting factors like IL-3 
and SCF, and late-acting lineage-specific factors such as colony stimulating factor-granulocyte 
macrophage (GM-CSF) and erythropoietin (Epo). IL-3 is a multipotent cytokine that stimulates 
primitive and also lineage-committed progenitors. SCF acts in combination with cytokines like IL-
land IL-6 to support multilineage colony formation . GM-CSF promotes the formation of myeloid 
colonies, while Epo is responsible for differentiation and maturation of erythroid cells [74]. 
Basic Fibroblast Growth Factor (bFGF) is a cytokine with pleiotropic effects on multiple cell types 
constituting the haematopoietic tissue. Basic FGF induces proliferation of bone marrow stromal 
cells and enhances the myeloid cell numbers as shown by the elevation in the number of adherent 
and non-adherent layer derived progenitor cells. It was noted that bFGF augments the effects of 
other cytokines on granulocyte-monocyte, erythroid, or mixed lineage colony formation . Basic FGF 




Seven controls from the 31 normal individuals (Appendix B) who are undergoing sternotomy for 
cardiac surgery were studied (controls 15-22, except for control 21 ). Their median age was 42 .8 
(range 19-64). Mononuclear cells (MNCs) were collected from the interface layer, washed three 
times with a-MEM, monocyte-depleted by means of plastic adherence and lymphocyte-depleted by 
addition of Cam path IM and complement. Refer to chapter 2 for a detailed method. 
3.2.1 Sources of Growth Factors 
Basic fibroblast growth factor was bought from Scio's Inc., Mountain View; CA. Epo was donated 
by Bioclones (Sand ton, Gauteng, South Africa) and once reconstituted to 1000 U/ml kept at 4 °C. 
Recombinant human cytokines were bought from Amgen, Thousand Oaks, CA; rhesus-lL-3 had a 
specific activity of 1 x 107 U/mg, rhesus-GM-CSF, G-CSF, or SCF had a specific activity of 1 x 108 
U/ml each, at a protein concentration of 0.5, 0.5, and 2 mg/ml respectively, and were diluted to 1 
µg/ml and stored at 4°C until used. 
3.3.2 Progenitor Cell Selection 
Refer to chapter 2 for a detailed method for the selection of CD34+ cells. 



















Epo 1, bFGF2 
Epo 1, bFGF 20 
Epo 1, IL3l0 
Epo 1, IL310, bFGF 2 
Epo 1, IL3 10, bFGF 20 
Epo l , GMlO, bFGF 2 
Epo 1, GMlO, bFGF 20 
Epo 1, IL310, SCF 20 
Epo 1, IL310, SCF 20, bFGF 2 
Epo 1, IL310, SCF 20, bFGF 20 
Epo= erythropoietin (lnglm/), bFGF= basic fibroblast growth factor, JL310= Jnterleukin-3 (JO nglml), GM JO = colony 
stimulating factor-granulocyte-monocyte (1 Ong/ml), SCF 20= stem cell factor (20 nglml). 
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3.3.2 Clonogenic Assay 
Selected CD34+ cells were cultured at concentrations between 1-5 x 103 in the presence of 5x10·5 M 
2 mercaptoethanol (ME), gentamicin and 30% FCS in the presence of the above-mentioned growth 
factors (Table 3 .1 ). An aliquot of O .25 ml of this suspension was added to each of the four-well 
dishes (Nunclon, Nunc, Denmark), covered with 0.3% agar and incubated for 14 days at 37°C in 5% 
CO2. 
For permanent recording, cultures were fixed in 0.25% glyteraldehyde for 7 minutes, mounted onto 
microscopic slides, and stained with MGG. Using an inverted microscope, burst forming unit-
erythroid (BFU-E) were recognized as haemoglobinised colonies composing of more than 99 cells 
or when aggregates consist of three or more sub clusters. CFU-E were described as erythroid clusters 
of 4-99 cells and CFU-GMs were defined as myeloid aggregates containing more than 40 cells. 
3.4 Statistical Analysis 
The program Basic Statistica was used to analyze the results and a specific analysis tool used was 
the t-test for dependent variables. Significance level was set at <0.05. Bar charts were constructed 
based on averages obtained from all the results . 
3.5 Results 
Of the total selected cell population a mean of 92.4% cells expressing CD34+ antigen were 
documented. These cells were cultured in duplicate at 5 x 103 /ml , in the presence of defined 
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Epo 1, bFGF2 
Epo 1, bFGF20 
Epo l , IL,10 
Epo 1, IL, 10, bFGF 2 
Epo 1, IL, 10, bFGF 20 
Epo 1, GM 10, bFGF 2 
Epo 1, GM 10, bFGF 20 
Epol,IL,10,SCF20 
Epo 1, IL, 10, SCF 20, bFGF 2 





























































































Data represents the clonogenic growth from 5 x J(f cultured cells scored after 14 days. AU denotes that there was no 
growth in any of the cultures. Different colony numbers (CFU-GM, BFU-E and CFU-EJ are compared with each other when 
the 0, 2 and 20 ng bFGF concentrations are used Statistical analysis was pe,fonned by the t-testfor dependent variables. 
Significance level was set at <O. 05. Epo= erythropoietin (lnglm/), bFGF= basic .fibroblast growth factor, JL310= 
lnter/eukin-3 (JO ng/ml), GM IO = colony stimulatingjactor-granulocyte-monocyte (I Ong/ml), SCF 20= stem eel/factor (20 
nglml). 
31 
3.5.1 Results of BFU-Es. 
When 5 x 103 CD34+ cells were exposed to bFGF alone, no clonogenic growth was noted (Table 3.2 
and Figure 3 .1 ). When similar numbers of cells were exposed to Epo and bFGF (2 and 20 ng/ml), 
erythroid bursts were increased, even though not significantly increased above those obtained in the 
presence ofEpo alone (p= 0.2 and 0.3). Results show that the low and high concentrations of bFGF did 
not augment the proliferation of immature erythrocytes, even when added with other growth factors 
(Table 3.2 and Figure 1). 
3.5.2 Results of CFU-Es 
Addition of Epo and bFGF (2 and 20 ng/ml) to cultures resulted in an insignificant augmentation in 
erythroid colony growth above those in the presence ofEpo alone (p= 0.4 and 0.7). Results in Table 3.2 
demonstrate that bFGF was unable to increase the colony numbers of mature erythrocytes even when 
supplemented with other growth factors . 
3.5.3 Results of CFU-GMs 
Myeloid colonies were insignificantly lower in cultures supplemented with Epo, IL-3 and SCF when 
compared to those found in the presence ofEpo, IL-3 , SCF and bFGF. Myeloid colonies in the presence 
of Epo, CSF-GM and bFGF 20 ng/ml were also insignificantly increased above colonies obtained in 
cultures treated with Epo, CSF-GM and bFGF 2 ng/ml (p=O. l ; Table 3.2). Data demonstrate that the 
low and high concentrations ofbFGF did not expand the number ofmyeloid colonies, even when added 
in conjunction with other growth factors. 
3.6 Discussion 
No colony growth is observed when bone marrow derived CD34+ cells are grown in the presence of 
bFGF These results correspond to those obtained by Berardi A. C, 1995 [l O]. Our results also show 
that there is no difference in all colony numbers when bFGF is added at low or high concentrations. 
There was no significant expansion of CD34+ cells when FGF was added to other growth factors . 
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It is known that proliferation of early and committed progenitors needs stimulation by combination of 
growth factors , but results obtained from this chapter demonstrate that bFGF in combinations with 3 or 
4 other growth factors was unable to elicit a significant augmentation on colony numbers . Although, 
SCF and bFGF have shown to be synergistic in expanding committed myeloid progenitor cell growth 
[34], this study was unable to confirm these observations. 
3. 7 Conclusion 
Results demonstrate that: 
• bFGF is unable to elicit an effect on the clonogenic growth of CD34+ cells, when it is added on 
its own to cultures. 
• bFGF at any concentration, is unable to induce significant proliferation of CD34\ even when 
added in combination with other growth factors. 
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CHAPTER4 
The effects of bFGF on normal fibroblastic progenitors and on the ability of normal stromal 
layers to support the clonogenic ability of CD34+ and the development of blastic colonies 
Objective: To obtain the optimum concentration to be used on patients who have undergone bone 
marrow transplantation, by using varying concentrations of bFGF on a normal population. 
4.1 Introduction 
In each assay the 0.2, 2 and 20 ng/ml bFGF with and without heparan sulphate were added in 
duplicate (Table 4.1). Heparan sulphate was added or omitted from cultures in order to determine 
if it has any effect on normal cells when added in conjunction with bFGF. Cultures not 
supplemented with either bFGF or heparan sulphate were regarded as control samples. Two 
different assays were employed: the CFU-Fs and stroma, as measured by the surface area covered 
by stroma and cell numbers enumerated after trypsinization of monolayers. 
Table 4.1. Different bFGF concentrations used in cultures 
Culture Number bFGF Concentration 
1 Control 
2 0.2 ng bFGF + 20 ng HS 
3 0.2 ng bFGF 
4 2 ng bFGF and 20 ng HS 
5 2 ng bFGF 
6 20 ng bFGF + 20 ng HS 
7 20 ng bFGF 
bFGF concentrations were added in the absence and presence of HS. ng= nanograms and HS 
stands for heparan sulphate. 
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4.2 Methods 
Bone marrow aspirates were drawn from thirty-one haematologically normal individuals 
undergoing sternotomy for cardiac surgery under general anaesthesia. The median age for this 
control group was 48 years (range 19 - 74; Appendix B). Informed consent for bone marrow 
collections was obtained. 
4.2.1 Stromal Assay 
This assay was carried out to evaluate the effects of bFGF on the proliferation of normal stromal 
cells. MNCs were cultured in the absence and presence of bFGF supplemented with heparan 
sulphate (Table 4 .1 ). Refer to chapter 2 for a description of the method. Investigations of the effect 
of bFGF in a dose-response study on the stromal confluence was done by placing culture dishes on 
a grid containing 1-mm squares and scoring the number of squares occupied by stromal layers as 
percentage area covered. 
4.2.2 Fibroblastic Progenitor (CFU-Fs) Assay 
This assay was performed to assess the effects of bFGF on normal fibroblastic progenitors. Bone 
marrow MNCs were cultured at a concentration of 1 x 106/5ml in the absence and presence of 
bFGF in 50 mm petri dishes. Fibroblastic progenitors were isolated from bone marrow cells by 
culturing MNCs in a-MEM supplemented with 20% FCS. Fibroblastic cells were incubated at 
37°C in 5% CO2 and media were changed on day 5. After 9 days of culture, supernatants were 
removed from the dishes, air-dried, fixed and stained with MGG. Aggregates of more than 20 cells 
were defined as CFU-Fs using an inverted microscope. 
4.2.3 Progenitor Cell Selection 
Refer to chapter 2 for the description of the method for the selection of CD34+ cells. Aliqouts of 
the selected cells were studied by the standard flow cytometry. 
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4.2.4 CFU-bl Assay 
This assay was performed to evaluate the effects of bFGF on the normal stromal capacity to 
support the clonogenic potential of CD34+ cells and the growth of normal blastic colonies. Selected 
CD34+ cells were layered on preformed stromal layers that have been treated with or without 
bFGF. Refer to chapter 2 for the description of the method. 
4.3 Statistical Analysis 
Statistical analysis was performed by the paired Student t-test. The Student t-test was used to 
demonstrate the study groups' distinction before and after the treatment. Significance level was set 
at <0.05 . 
4.4 Results 
4.4.1 Appearance of Bone Marrow Stroma 
Stromal confluence was scored at 3 weeks of culture, since stromal layers cultured in the presence 
ofbFGF appeared to be confluent within 3 weeks. 
Picture 4A 
Picture 4A. A stromal layer from a normal individual, cultured from 0.5 x 106/ml MNCs for 3 
weeks in the absence of bFGF. 
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Picture 4B 
Picture 4B. Strama/ layer from a normal individual, culturedfrom 0.5 x 1061ml MNCs for 3 
weeks in the presence of bFGF. 
Stromal layers cultured in the absence of bFGF grew into a monolayer (Picture 4A), whilst stromal 
layers cultured in the presence of bFGF grew at high densities, in multilayers and different 
directions (Picture 4B), as shown by Wilson, et al, 1991 [103]. Microscopically, fibroblasts in 
stroma supplemented with bFGF were more elongated and formed a denser background than 
fibroblasts in stromal layers cultured in the absence of bFGF (Picture 4B vs. 4A). Fat cells in 
bFGF-treated cultures started becoming visible after 2 weeks of culture and appeared increased in 
number and size (Picture 4B). 
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Table 4.2. The effect of bFGF on the proliferation of normal bone marrow stromal cells 
Culture % Confluence (Median) Range P=Value 
Control 55 30-65 
0.2 ng bFGF + HS 47.5 35-60 NS 
0.2 ng bFGF 50 30-60 NS 
2 ng bFGF+HS 70 50-95 <0.05 
2 ng bFGF 65 50-80 0.0006 
20 ng bFGF + HS 80 65-99 0.004 
20 ng bFGF 77.5 70-98 <0.05 
Mononuclear cells 0. 5 x 106/ml were incubated in the absence and presence of varying bFGF 
concentrations, in a-MEM supplemented with 15% of each FCS and horse serum, 2 x 10·7 HC for 21 days. 
Data represents median confluence in percentages, ranges and p-values. NS represents values that are not 
significant. 
Mononuclear cells from normal individuals were cultured at a concentration of 0.5 x 106/ml in 35 
mm dishes for 3 weeks, in the absence and presence of the above-mentioned bFGF concentrations 
(Table 4.1). The median surface area covered by stromal layers was 55% (range 30-65), and the 
area covered was significantly improved with the addition of 2 and 20 ng/ml bFGF with and 
without 20 ng/ml heparan sulphate (Table 4.2). 
4.4.2 Stromal Cell Numbers 
Table 4.3. The effect of bFGF on the proliferation of bone marrow stromal cells 
Culture Cell Number x 106/2ml Range P=Value 
Control 0.61 0.15-1.66 
0.2 ng bFGF + HS 0.61 0.12-1.67 NS 
0.2 ng bFGF 0.83 0.32-1.99 NS 
2 ngbFGF+HS 1.27 0.27-4.11 0.03 
2 ng bFGF 0.83 0.29-1.36 NS 
20 ng bFGF + HS 1.47 0.44-1.89 0.03 
20 ng bFGF 1.09 0.33-1.76 NS 
Cells 0. 5 x 1061ml cultured in duplicate, supplemented with various bFGF concentrations formed stromal 
layers for 21 days and were incubated with 5% trypsin solution/or 10 minutes. Strama/ cell numbers are 
expressed as medians and significant values are given by the paired t-test. NS stands for not significant. 
38 
Single cell suspension from trypsinized stromal layers was prepared to determine the effects of 
vanous concentrations of bFGF. Stromal cell numbers in the dishes were enumerated with a 
particle counter. Stromal layers established at 0.5 x 106/ml mononuclear cells produced 0.61 x 
106/2ml cells (range 0.15-1.66). Strama! cells increased significantly upon the addition of 2 and 20 
ng/ml with 20 ng/ml heparan sulphate (p=0.03 each; Table 4.3) 
4.4.3. Fibroblastic Progenitors (CFU-Fs) 
Picture 4C 
Picture 4C. Fibroblastic progenitor from a normal individual cultured at 1 x J06/5mlfor 9 days in 
the absence of bFGF and stained with MGG. 
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Picture 4D 
Picture 4D. Fibroblastic progenitors from a normal individual cultured at 1 x 106/5mlfor 9 days 
in the presence of bFGF and stained with MGG. 
Basic FGF increased fibroblastic colony sizes, but the colonies expanded and became confluent in 
such a way that it was very difficult to quantitate them (Picture 4D), unlike the discrete fibroblastic 
colonies obtained in the absence ofbFGF (Picture 4C). 
Table 4.4. The effect of bFGF on the growth of fibroblastic progenitors 
Culture CFU-F x 10c;/5ml Range P-Value 
Control 28.3 14-53 
0.2 ng bFGF + HS 28 .0 3-67 NS 
0.2 ng bFGF 18.5 12-25 NS 
2 ngbFGF+HS 23.6 14-36 NS 
2 ng bFGF 19.9 11-34 0.05 
20 ng bFGF + HS 23.0 7-40 NS 
20 ng bFGF 16.2 5-28 0.05 
Fibroblastic progenitors were established at a concentration of 1 x 10615ml in a-MEM supplemented with 
20% FCS for 9 days. Fibroblastic colony results are expressed as medians and the significance level was set 
at <0.05. 40 
Following 9 days of incubation, fibroblastic cultures were terminated, fixed and stained with MGG 
and colony numbers scored using an inverted microscope. Fibroblastic colony numbers were 
significantly increased in control samples (median 28 .3 x 106/Sml CFU-Fs; range 14-53), but the 
addition of bFGF to cultures did not change the number of fibroblastic colonies. The highest 
concentration of bFGF appeared to be inhibitory on fibroblastic colony numbers (Table 4.4). 
4.4.4. Blastic colonies (CFU-bl) 
Picture 4E 
Picture 4E. A blastic colony (centre) obtained when normal CD34+ cells were panned on normal 
stroma in the absence of bFGF. 
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Picture 4F 
Picture 4F. Elastic colonies obtained when normal CD34+ cells were cultured on normal stroma 
that was supplemented with bFGF. 
Stroma-adherent cells forming a blastic colony on a stromal layer that was cultured in the absence 
of bFGF were small and loose (Picture 4E). Normal blastic colonies obtained from bFGF-treated 
stromal layer were increased in number and larger than those found in control cultures (Pictures 4E 
vs. 4F). 
Table 4.5. The effect of bFGF on normal stroma-adherent colonies 
Culture CFU-bl x 104/ml Range P-Value 
Control 121.8 3-184 
0.2 ng bFGF + HS 104.0 21-159 NS 
0.2 ng bFGF 106.1 16-218 NS 
2 ngbFGF+HS 132.8 41-260 NS 
2 ng bFGF 107.3 7-176 NS 
20 ng bFGF + HS 156.8 43-271 0.03 
20ngbFGF 114.5 8-207 0.01 
Monocyte and lymphocyte depleted selected 1 x 104 CD34+ cells were layered in duplicates, in cross-culture 
assays on normal preformed stromal layers. Cells were incubated for 2 hours to allow optimal adherence. 
Stroma non-adherent cells were washed off the dishes and stroma-adherent cells were covered with 0. 3% 
agar and cultured for 6 days. Elastic colony results are expressed as medians. 
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Selected normal cells expressing CD34+ antigen had a mean percentage of 92.4% of the total 
selected cell population. The median number of blastic colonies from normal individuals in the 
absence of bFGF was 121.8 x 104/rnl CFU-bl (range 3-184). This score was significantly higher 
upon the addition of 20 ng/rnl bFGF with 20 ng/rnl heparan sulphate (median 156.8 vs. 121.8 CFU-
bl; range 43-271), but significantly lower with the addition of 20 ng/rnl bFGF without 20 ng/rnl 
heparan sulphate (median 114.5 vs . 121.8 CFU-bl; Table 4.5). Basic FGF concentration without 
heparan sulphate was inhibitory. 
4.5 Discussion 
Results show that there is a greater increase in the proliferation rate of normal stromal layers in the 
presence of bFGF than the rate of normal stromal layers cultured in the absence of bFGF. There is 
no significant effect on the surface area covered when the 0.2 ng/rnl bFGF with and without 20 
ng/ml heparan sulphate is added to cultures. Heparan sulphate has an incremental effect on the 
surface area covered by stroma when it is added in conjunction with bFGF, since stromal layers 
cultured in the presence of bFGF and heparan sulphate grow better than those stromal layers 
cultured in the presence ofbFGF alone (without heparan sulphate). 
Stromal cell numbers from cultures treated with bFGF were significantly increased above those cell 
numbers from control cultures with no bFGF. Basic FGF concentrations supplemented with 
heparan sulphate have a more significant effect on stromal cell numbers than those bFGF 
concentrations without heparan sulphate, indicating that heparan sulphate has a major additive 
effect on stromal cell numbers when added in conjunction with bFGF. 
Results show that even though bFGF is unable to increase fibroblastic colony numbers above those 
of the controls, it has an effect on the sizes of the colonies, as they become larger in the presence of 
bFGF than colonies in the absence ofbFGF. 
Addition of 20 ng/ml bFGF accounts for greater proliferation of normal stroma-adherent CD34+ 




Data from this chapter demonstrates that: 
• bFGF does not increase the number of fibroblastic progenitors, but only augments colony 
sizes. 
• 0.2 ng/ml bFGF is ineffective in all the culture assays even when added in conjunction with 
heparan sulphate. 
• 2 and 20 ng/ml with 20 ng/ml heparan sulphate elevate both proliferation rate of stromal 
layers to be confluent within 3 weeks and also increase stromal cell numbers. 
• 20 ng/ml bFGF with 20 ng/ml heparan sulphate significantly augments blastic colony 
numbers and increases their colony sizes. 
The effects of 2 and 20 ng/ml bFGF with 20 ng/ml heparan sulphate will then be studied in vitro on 
patients who have undergone either autologous or allogeneic peripheral blood stem cell 
transplantation, in order to evaluate whether they will be able to repair impaired haematopoiesis. 
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CHAPTERS 
Effects of bFGF on the bone marrow microenvironment in the recovery stage following 
transplantation. 
Objectives: 
• To evaluate the modulatory effects of bFGF when it is added to growing stromal layers and 
fibroblastic progenitors. 
• To assess the effects of bFGF on the defective stromal supportive capacity and reduced 
clonogenic potential of bone marrow derived CD34+ cells following PBSCT. 
• To compare the results obtained from this chapter to those found in normal individuals. 
5.1 Patient Population 
Sixteen subjects with blood disorders who had undergone autologous (n=3) or allogeneic (n=13) 
peripheral blood stem cell transplantation (PBSCT) were studied. Patients were studied at 6 and 12 
months in complete remission of their blood disorders following PBSCT and a control group was drawn 
from haematologically normal individuals undergoing sternotomy for cardiac surgery. None of the 
patients or normal individuals had a history of recent inflammation or infectious disorder at the time of 
investigation. Informed consent was always acquired from patients according to the guidelines provided 
by the Ethics and Research Committee of the University of Cape Town and Groote Schuur Hospital. 
The median age of patients was 41.5 years (range 17-57) while the median age of normal individuals 
was 48 years (range 19-74). Refer to Table 5.1 for clinical data of patients. 
Table 5.1. Clinical data of patients 
Patient Diagnosis 
Acute Myeloid Leukaemia 
Non-Hodgkin's Lymphoma 
Chronic Myeloid Leukaemia 
Acute Lymphoblastic Leukaemia 
Severe Aplastic Anaemia 
Myelodysplastic Syndromes 







Type of Transplantation 
Autologous 





Data represents the number of patients, their diagnosis and the type of bone marrow grafts they 
received. 
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The preconditioning of patients for transplantation included 120 mg/kg of cyclophosphamide (Cy), 12 
Gy of fractionated total body irradiation (TBI) and 6 Gy of total nodal irradiation (TNI). Bone marrow 
from patients was aspirated under intramuscular pethidine HCL ( 1 mg/kg of body weight) analgesia 
given 30 minutes prior to the local anaesthetic administration. 
5.2 Methods 
For mononuclear cells preparation, refer to chapter 2 for a description of the method. 
5.2.1 Stromal Assay 
This assay was performed to evaluate the effects of bFGF on patients' strornal layer development in the 
recovery stage following transplantation and compared to strornal layers from normal samples. For the 
concentration and conditions used for the establishment of stromal layers, refer to chapter 2 for a 
description of the method. Stromal layers were cultured in the absence and presence of the 2 and 20 
ng/ml bFGF with 20 ng/ml heparan sulphate. 
5.2.2 Fibroblastic Progenitor Assay 
This assay was performed to measure the effects of bFGF on the fibroblastic progenitors from patients 
receiving transplantation and compared to those from normal individuals. Refer to chapter 4 for a 
description of the method. Fibroblastic colonies from patients were cultured in the absence and presence 
of 2 and 20 ng/ml bFGF with 20 ng/ml heparan sulphate. 
5.2.3 Progenitor Cell Selection 
Refer to chapter 2 for a description of the method for the selection of CD34+ cells. Aliqouts of selected 
cells from patients were studied by standard flow-cytometry. 
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5.2.4 Blastic Colony Assay 
This assay was carried out to assess the effects of bFGF on the ability of patients' CD 34+ cells to 
proliferate and form blastic colonies on normal preformed stroma. Furthermore, the effects of bFGF on 
the impaired stromal supportive capacity, was evaluated. Normal CD34+ cells were also cultured on 
normal strorna in order to provide comparative results. Blastic colony assay was performed in the 
absence and presence of the 2 and 20 ng/rnl bFGF with 20 ng/ml heparan sulphate. Refer to chapter 2 
fo r a description of the method. 
5.3 Statistical Analysis 
Statistical analysis was performed by both the student t-test and paired test, comparing normal cells and 
patients ' cells cultured in the presence of bFGF. Significance level was set at <0.05. 
5.4 Results 
5.4.1 Appearance of Bone Marrow Stroma 
Picture SA 
Picture SA. Strama/ layer from a patient cultured at 0.5 x106/ml mononuclear cells f or 3 weeks in the 
absence of bFGF 
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Picture SB 
Picture SB. Strama/ layer from a normal individual cultured at 0.5 xl 0
6/ml mononuclear cells for 3 
weeks in the absence of bFGF. This stromal layer is patchy, as one could visualize a band where stroma 
is covering the surface area of the dish and the other parts of the dishes where there is no stroma at all. 
Picture SC 
Picture SC. Strama/ layer from a patient cultured at 0.5 x106/ml mononuclear cells for 3 weeks in the 
presence bFGF. One could visualize large globules of fat cells and stroma is covering almost the whole 
suiface of the dish. There are lots of macrophages in the stroma. 
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Results show that stromal layers cultured in the presence of bFGF grew in multilayers. It was possible 
to visualize different directions of the growing fibroblasts. This improvement in stromal layers could 
match stromal layers from normal individuals cultured in the absence of bFGF (Pictures 5C vs. 5A). Fat 
cells in bFGF-supplemented cultures appeared increased in size as a result of their larger globules. 
Macrophages in bFGF-treated cultures also appeared increased in numbers when compared to those in 
control culture dishes and normal individuals (Pictures 5C vs. 5A and 5C). 
Table 5.2. The effect of bFGF on the growth of patients' stromal cells 
Culture Median Confluence Range Comparison between normal, 
(%) 2 and 20 ng bFGF 
Normal 50 40-65 
Control 40 0-55 0.0001 
2 ng/ml bFGF 62.5 0-88 0.47 
20 ng/ml bFGF 78 20-98 0.001 
0.5 x 106/ml cells were cultured in the absence and presence of 2 and 20 ng bFGF with 20 ng/ml 
heparan sulphate, in a-MEM supplemented with 15% of each FCS, horse serum and 2 x 10-7 M HC. 
They were incubated at 37°C in 5% CO2 for 21 days. The last column gives a comparison between the 
area covered in normal individuals and in patients in the absence and presence bFGF concentrations. 
Sign.ificance level was set at < 0. 05. 
Mononuclear cells from patients undergoing transplantation were cultured in 35 mm petri dishes for 3 
weeks, in the presence of 0, 2 and 20 ng/ml bFGF with 20 ng/ml heparan sulphate. The median surface 
area covered by stromal layers in normal and patients' samples was 50 and 40% respectively. The 
surface area improved upon the addition of 2 ng/ml bFGF (62.5 vs. normal 50%; p=0.47), and 
significantly increased with the addition of20 ng/ml bFGF (78 vs. normal 50%; p=0.001; Table 5.2). 
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5.4.2 Stromal Cell Numbers 
Table 5.3. The effect of bFGF on the proliferation of patients' stromal cells 
Culture Cell Numbers x Range Comparison between 
10612ml (Median) normal, 2 and 20 ng bFGF 
Normal 0.61 0.15-1.66 
Control 0.66 0.28-1.73 0.1 
2 ng/ml bFGF 1.44 0.25-2.8 0.003 
20 ng/ml bFGF 2.11 0.46-3.4 <0.05 
MNC cultured for 21 days were quantitated by addition of 5% trypsin solution to stromal dishes for 10 
minutes. Single cell suspensions were washed off the dishes and stromal cells counted with a particle 
counter. The paired t-test gives a comparison between normal, 2 and 20 ng/ml bFGF and 20 nglml 
heparan sulphate. Significance level was set at <O. 05. 
Single cell suspensions from trypsinized stromal layers supplemented with 0, 2 and 20 ng/ml bFGF 
were prepared in order to determine the effects of bFGF on stroma. Monolayers established with 0.5 x 
10
6
/ml mononuclear cells in patients produced 0.66 x 10
6/2ml cells (range 0.15-1.66 vs. normal 0.61) 
and they increased significantly with the addition of 2 and 20 ng/ml bFGF with 20 ng/ml heparan 
sulphate (p=0.003 and <0.05; Table 5.3). 
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5.4.3 Fibroblastic Progenitors 
Picture SD 
Picture SC. Fibroblastic progenitor from a patient cultured at 1 x 10615ml for 9 days in the absence of 
bFGF and stained with MGG. 
Picture SE 
Picture SE. Fibroblastic progenitor from a normal individual cultured at 1 x 106/5mlfor 9 days in the 




Picture SF. Fibroblastic progenitor from a patient cultured at 1 x 10615ml for 9 days in the presence of 
bFGF and stained with MGG. Picture shows many colonies that have grown towards each other, 
therefore forming one large colony. 
Patients' fibroblastic progenitors cultured in the presence of bFGF occupy almost the whole surface 
area of the dish, in such a way that colonies were difficult to quantitate. Fibroblastic colonies from 
normal individuals and controls cultured in the absence of bFGF were discrete and easily quantitated 
(Pictures SF vs. SD and SE). 
Table 5.4. The effect of bFGF on growth of patients' fibroblastic progenitors 
Control CFU-F x 106/Sml Range Comparison between normal, 
(Median} 2 and 20 ng bFGF 
Normal 28.3 14-53 
Control 7 5-28 0.0001 
2 ng/ml bFGF 10 3-33 0.001 
20 ng/ml bFGF 9 4-33 0.002 
MNCs were cultured in a-MEM supplemented with 20% FCS for 9 days. The last column compares the 
normal, 2 and 20 ng/ml bFGF and 20 ng/ml heparan sulphate. Statistical analysis was given by the 
pa.ired t-test and significance level was set at < 0. 05. 
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Following 9 days of incubation, fibroblastic colony cultures were terminated, fixed, stained with MGG 
and colonies scored using an inverted microscope. The median fibroblastic colony numbers in normal 
individuals were 28.3 x 106/5ml (range 14-53), and these values increased above those in control 
samples (median 28.3 vs. 7 x 106/5ml; p=0.0001). The addition of 2 and 20 ng/ml bFGF with 20 ng/ml 
heparan sulphate did not change the colony numbers (10 and 9 vs. 28.3; Table 5.4). 
5.4.4 Blastic colonies 
Normal or patients ' selected cells expressing CD34+ antigen was 92.4 or 89.4% of the CD34+ 
population respectively. Selected CD34+ cells were layered m duplicate in cross-culture studies on 
normal or patients ' preformed stroma. Normal CD34+ cells were also cultured on normal stroma m 
order to provide comparative results. 
Picture SG 
Picture 5G. Elastic colonies obtained when normal 1 x 104/ml CD34+ cells were layered on patients' 
stroma in the absence of bFGF 
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Picture 5H 
Picture 5H. Elastic colonies obtained when normal 1 x 104/ml CD34+ cells were panned on normal 
stroma in the absence of bFGF 
Picture 51 
Picture 51. Elastic colonies obtained when normal J x J 041ml CD34+ cells were cultured on patients' 
stroma in the presence of bFGF 
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Blastic colonies from patients cultured in the presence of bFGF were larger, matching those blastic 
colonies obtained from normal individuals in the absence of bFGF (Pictures 51 vs. 5H). One could 
visualize that patients' stroma-adherent cells making up a blastic colony, in the absence of bFGF, are 
small and tend to be loose from each other (Picture 5G). On the other hand, stroma-adherent cells from 
a patient cultured in the presence of bFGF formed firm and discrete colonies (Pictures 5G vs. 51). 
Table 5.5. Effect of bFGF on the proliferation of patients' CD34+ cells on normal preformed 
stroma compared to proliferation of normal CD34+ cells on normal stroma 
Control CFU-bl x 104/ml Range Comparison between normal, 
(Median) 2 and 20 ng bFGF (P=Value) 
Normal 90 24-139 
Control D6=40 3-121 0.009 
D9=37 5-130 
D11=36 5-215 
2 ng/ml bFGF D6=64.5 6-193 0.3 
D9=70.5 6-201 
Dl 1=51 24-331 
20 ng/ml bFGF D6=85 5-228 0.7 
D9=96 6-255 
Dl 1=80 13-423 
Results of blastic colonies when patients cells were layered on nonnal stroma which was treated with 2 
and 20 ng bFGF and cultured for 6, 9and11 days. The second row represents blastic colonies obtained 
when nom1al CD34+ cells were layered on to normal stroma, covered with 0. 3% agar and incubated for 
6 days. The last column compares the nonnal, 2 and 20 ng/ml bFGF with 20 ng/ml heparan sulphate. 
Statistical analysis was given by the paired t-test and significance level was set at <O. 05 
The median number of CFU-bl when normal 1 x 104/rnl CD34+ cells were cultured on normal stroma 
was 90 x 104/rnl (range 24-139). Blastic colony numbers in patients were significantly lower (median 40 
x 104/ml; range 3-121; p=0.009), but improved upon the addition of 2 and 20 ng/ml bFGF, matching 
blastic colony scores from normal individuals (64.5 and 85 vs. normal 90 x 104/ml; Table 5.5). 
55 
Table 5.6. Effect of bFGF on the proliferation of normal CD34+ cells on patients' preformed 
stroma and compared to the proliferation of normal CD34+ cells on normal stroma. 
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Results of blastic colonies when normal CD34+ cells were cultured for 6, 9 and 11 days, on patients' 
stroma which was treated with 2 and 20 ng bFGF The second row represents blastic colonies obtained 
when normal CD34+ cells were layered on to normal stroma, covered with 0. 3% agar and incubated for 
6 days. The last column compares the normal, 2 and 20 ng/ml bFGF with 20 ng/ml heparan sulphate. 
Statistical analysis was given by the paired t-test and significance level was set at < 0. 05. 
The median number of CFU-bl when normal CD34+ cells were layered on normal stroma was 90 x 
104/rnl (range 24-139). Blastic colony scores when normal CD34+ cell were panned on patients' stroma 
was 39 x 104/rnl (range 6-84), but improved significantly upon the addition of 2 ng/ml bFGF (60 x 
10
4/rnl CFU-bl; p=0.05) . The addition of 20 ng/ml bFGF gave blastic colony scores which were higher 
than those in control samples (91 vs. 39 x 10
4/ml CFU-bl), and matching colony scores from normal 
individuals (91 vs. normal 90 CFU-bl; Table 5.6) 
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5.5 Discussion 
In vitro, abnormalities that follow recovery from stem cell transplantation include: failure of the stromal 
layer to cover the whole surface area of the dish, and poor stromal support to the growth of blastic 
colonies. 
Data demonstrates that stromal layers formed by patients' cells cultured in the absence of bFGF cover a 
lesser area than the area covered by stromal layers in normal individuals and this finding supports the 
observation found in bone marrow transplantation by Novitzky et al, 1995 [70]. Patients' cells cultured 
in the presence of bFGF occupy a greater surface area than the area covered by stromal layers in normal 
individuals and controls. The other finding is that bFGF accelerates the proliferation rate of the stromal 
cells, since stromal layers in its presence become confluent within 3 weeks, while stromal layers 
cultured in the absence of bFGF initiated at the same time, are still irregular. 
Basic FGF also improves the appearance of fat cells and fibroblast in patients ' stromal cultures, 
providing a better background and environment for haematopoietic cells to survive, proliferate and 
differentiate. 
Results also show that patients' stromal cell numbers in the presence of bFGF are significantly 
increased above those cell numbers in controls and normal individuals. Augmentation in patients' cell 
numbers in the presence of bFGF corresponds to the results of surface area covered by stroma, since 
surface area covered in the presence of bFGF is also increased above that in normal individuals. 
Patients' cell numbers cultured in the absence of bFGF are increased above cell numbers from normal 
individuals, but are not significantly different from each other. 
Basic FGF stimulates the growth of fibroblasts and this is supported by the fact that colonies from 
patients' samples, in its presence, are larger and growing towards each other as compared to colonies in 
control samples (which are small, discrete and easily counted) . These results show that bFGF might not 
have an incremental effect on the number of fibroblastic progenitors, but it does increase the sizes of the 
colonies. 
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Results also demonstrate that bFGF significantly elevates the clonogenic capacity of patients' cells only 
when used at the highest concentration, which is the 20 ng/ml. This increase in patients' blastic colonies 
match blastic colony scores obtained when normal cells are cultured on normal stroma. This means that 
patients' CD34+ cell cultured in the presence of 20 ng/rnl bFGF have similar clonogenic potential as 
normal CD34+ cells cultured in the absence ofbFGF. 
Basic FGF also improves the integrity of patients' stroma since it supports the growth normal blastic 
colonies better. This statement is supported by the fact that colony numbers obtained on patients' 
stroma are the same as the colony scores found when normal CD34+ are layered on to normal stroma. 
This means that patients' stroma in the presence of bFGF supports normal blastic colonies in the same 
manner as normal stroma in the absence of bFGF. 
For a comparative analysis, data was inadequate to illustrate similarities or differences in patients 
receiving allogeneic and autologous grafts, since there were more allogeneic patients (n=l3) than those 
receiving autologous (n=3). The difference between patients studied at 6 and 12 months was also not 
evaluated since more patients were studied at 6 months (n=l l) and few at 12 months (n=5) . 
5.6 Conclusion 
Patients' stromal cells in the presence of bFGF proliferate faster than normal stromal cells. It was 
further illustrated that bFGF does not augment patients' fibroblastic colony numbers, but only increases 
the sizes of the colony. It improves the clonogenic capacity of patients' cells, which is associated with 
greater proliferation of patients' CD34+ leading to increased number of blastic colonies. The integrity of 
patients' stroma is also improved in that more cells adhere to stroma, leading to an increased 
proliferation of those adhered cells. 
In conclusion, basic Fibroblastic Growth Factor has the following in vitro effects on patients who had 
undergone peripheral stem cell transplantation: 
• Improves the proliferation rate of patients' stromal layers above that of a normal population. 
• Significantly elevates patients' stromal cell numbers above normal stromal cell numbers . 
• Unable to increase fibroblastic colony numbers above those in normal individuals. 




Normal haematopoiesis 1s characterized by the balanced interplay between haematopoietic 
stem/progenitor cells, molecules and cells that form part of the microenvironment. Cell adhesion 
molecules (CAMs) expressed on the cell surfaces of the haematopoietic stem/progenitor cells bind to 
specific ligands on the stromal cells and the extracellular matrix (ECM) components. 
This interaction is important in that haematopoietic cells will be in contact with the growth factors 
produced by the stromal components. Heparan sulphate proteoglycans (HSPGs) also play an important 
role in haematopoiesis because they bind to growth factors and present them in an active form to the 
haematopoietic cells within the microenvironrnent. This haematopoietic microenvironment is a highly 
organized structure where stem cells interact closely with the marrow stroma, and any alterations in the 
microenvironment may result in abnormal production of blood cells. 
In an attempt to eradicate these malignancies, bone marrow or peripheral blood stem cell transplantation 
is employed. Abnormal cells are replaced with bone marrow stem cells derived from either another 
individual or with a previously harvested portion of the patients' own marrow. Patients who participated 
in this study were in complete remission of their haematological malignancies at 6 or 12 months post-
transplantation. Bone marrow recipients in this study were of either related or unrelated stem cell grafts. 
It was described by Novitzky et al (1995) that following autologous or allogeneic transplantation, 
derangement in the proliferation and function of the bone marrow stroma and of selected CD34+ cells 
was noted. It was shown by the poor stromal supportive capacity and a reduction in the clonogeneic 
potential of the stroma adherent CD34+ cells, which did not recover even 8 years after transplantation. 
In a further study, the use of blood stem cells for transplantation showed a more favourable 
development of the stroma. This improved proliferation of stromal elements and support for the 
multiplication of CD34+ cells suggests that a large progenitor cell pool or harvest of elements that may 
be important for the formation of the stroma lead to a partially corrected haematopoiesis although the 
origin of the stroma was not tested. Given the above defects, basic fibroblast growth factor (bFGF) is 
considered to be a potentially useful cytokine to induce correction of these abnormalities. 
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This growth factor was chosen, as it was shown to be a multifunctional cytokine that accelerates the in 
vitro formation of the stromal cell layer and increases the number of adherent and non-adherent cells in 
the stroma. 
Basic FGF was used to supplement medium for culturing post-transplantation stromal layers. In 
patients, bFGF induced stroma to cover the entire surface growth area by increasing the number of cells 
in the stromal layer, so that when haematopoietic cells are generated they can survive and proliferate in 
close contact with this stromal layer. This means that bFGF restores the damaged stromal components 
and provides a suitable environment for the haematopoietic progenitor cell survival. 
Fibroblastic colonies in bFGF-untreated cultures are discrete and their numbers are more accurately 
enumerated than those colonies in bFGF-supplemented cultures. During our study period, colonies in 
bFGF-supplemented cultures covered the whole surface area of the dish to the extent that they were 
difficult to count and this is a limitation of this study, as it is based mainly on quantitative 
measurements. 
Basic FGF increases this clonogeneic potential CD34+ cells onto preformed stroma leading to the 
proliferation of more cells. In this study it is noted that in the presence of bFGF, blastic colony numbers 
from patient are increased to a greater extent than colony numbers from the same patients in the absence 
ofbFGF. 
Data demonstrate that bFGF improves the impaired patients' stroma, to be a more suitable, better 
environment for the growth, proliferation and differentiation of the haematopoietic cells. Stromal cells 
in its presence are able to cover the available growth surface area, thereby releasing the necessary 
growth factors needed for specific effects on the haematopoietic stem cells and in this way 
haematopoiesis is improved. 
Future Intentions 
The future direction of this study will be to look at the in vivo effects of bFGF in animals. A murine 
FGF will be obtained and employed in the animal study to assess the morphological effects of this 
growth factor and comparing them with the in vitro results obtained. Provided this protein is not toxic to 
animals, animals will undergo transplantation and the cytokine will be used in vivo. If similar in vitro 
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• 6g of commercially bought agar was dissolved in 200 ml of distilled water and brought to boil 
until it was clear and with bubbles. It was autoclaved at 115°C for 10 minutes. Volumes of 3 ml 
were aliquot in to bottles and stored at room temperature until use. 
AB Serum 
• This was supplied by the Western Province Blood Transfusion Services and aliquot in to 5 ml 
Cryopreservation tubes and stored at -70°C until use. 
0.83% Ammonium Chloride (NH4CL) 
• 2.49g of ammonium chloride was dissolved in 300 ml of distilled water and boiled for 10 
minutes. It was autoclaved at l 15°C. 
Alpha Minimal Essential Medium (a-MEM) 
• One vial was mixed with 2.2g of sodium bicarbonate (NaHC03) and dissolved in 1000 ml of 
distilled water. The mixture was stirred until the pH was between 7.1-7.25 and filtered using 0.2 
µmm diameter media caps into 200 ml volumes and stored in 4°C fridge. 
Basic Fibroblast Growth Factor (bFGF) 
1 mg/ml stock was diluted with sterile phosphate buffered saline (PBS) m to 100 and 1000 ng 
concentrations and stored at 4 ° c. 
Buffer (pH 6.8) 
• One tablet was dissolved in 1000 ml of distilled water and stored at room temperature. 
Campath lM 
• It was commercially bought in a vial of 2 ml volume and stored at -70°C. 
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Foetal Calf Serum (FCS) 
• This was also bought from Gibco and aliquot in to 15 ml volumes and stored in -70°C. 
Gentamycin (1:5 dilution) 
• 2 ml of gentamycin was diluted with 8 ml of commercially bought sterile water, aliquot into 0. 5 
ml volumes and stored at 4°C. 
Giemsa for staining CFU-F dishes 
• 2 ml of Giemsa stain was diluted with 70 ml of pH buffer and filtered using a 150 mm filter 
paper. 
Giemsa for staining slides 
• 2 ml of Giemsa stain was diluted with 140 ml of pH 5.8 buffer and filtered using a filter paper. 
Glyteraldehyde (0.25%) 
• 5 ml of glyteraldehyde was diluted with pH 6. 8 buffer to the 50 ml mark in a fat tube. 
Heparan Sulphate 
• 0.5 mg/ml powder was dissolved in distilled water to get concentration of 200 ng/ml and stirred 
on a magnetic stirrer. It was autoclaved at 115°C and cooled down before it was stored in 4 °C. 
Horse Serum 
• It was commercially bought from Gibco, aliquot into 15 ml volumes and stored at -70°C until 
use. 
Hydrocortisone 
• One vial was reconstituted with 2 ml of commercially bought sterile water, aliquot in to 0.1 ml 
volumes and stored at -70°C. 
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Iscove' Modified Dulbecco Medium (IMDM) 
• One vial mixed with 3.2g of sodium bicarbonate (NaHC03) was dissolved in 1000 ml of 
distilled water. It was filter using media cap of 0. 2 µmm pore diameter in to storing bottles at 
4°C. One sample was sent to the Microbiology laboratory to check for any bacteria growth and 
another sample was left in 37°C incubator for 3 days. 
May-Grunwald for staining CFU-F 
• Prepared by weighing 5g of May-Grunwald powder and transferred in to a conical flask of 5000 
ml volume and filled up to the mark with methanol. The mixture was placed on a stirrer for 1 
hour and then put in a water bath of 56°C for 15 minutes. The mixture was allowed to stand for 
24 hours with occasional mixing and filtered using a filter paper. This is a modified method by 
Dacie J. V, and Lewis S.M, Practical Haematology, 8th Edition, 1995, page 85. 
May Grunwald for staining slides 
• 20 ml of the stain was diluted with 150 ml of buffer pH 5.8 and filtered using a filter paper. 
Phosphate Buffered Saline (PBS) 
• Three tablets of buffered saline were dissolved in 300 ml of distilled water and put on the mixer. 
It was sent for autoclaving. 
5% Trypsin 
• One vial of trypsin powder was reconstituted with 10 ml of commercially bought sterile water 
when it was ready to be used. 
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APPENDIXB 
Age group of normal individuals 
CONTROLS AGE GENDER 
Control I 57 Male 
Control 2 27 Male 
Control 3 39 Male 
Control 4 68 Male 
Control 5 29 Male 
Control 6 58 Male 
Control 7 41 Female 
Control 8 68 Male 
Control 9 67 Male 
Control IO 48 Female 
Control II 74 Female 
Control 13 44 Female 
Control IS 43 Male 
Control 16 35 Female 
Control 17 46 Male 
Control 18 19 Female 
Control 19 32 Male 
Control 20 61 Male 
Control 21 45 Female 
Control 22 64 Male 
Control 23 67 Female 
Control 24 48 Female 
Control 25 43 Female 
Control 26 70 Female 
Control 27 68 Female 
Control 28 43 Female 
Control 29 71 Male 
Control 30 52 Female 
Control 31 50 Male 
Control 32 42 Male 













The primary and secondary colony forming unit- fibroblasts (CFU-Fs) 
were established at the concentrations shown below in 80 mm petri dishes. 
The cells were cultured with 20% FCS/---MEM FOR 3 or 9 days at 
concentrations shown below. Plates were stained with 
May -Grunwald- Giemsa. 
Plating concentration: primary= 1 x 10615ml (9 DAYS) 
Secondary= 0.05 x 10615ml (3 DAYS) 
NAMES A B C D E F G 
Control # 8 primary 30 39 17 36 32 16 
Control # 9 primary 53 67 34 37 19 
Control# 10 primary 18 21 20 15 10 
Control # 11 primary 23 22 11 23 11 7 5 
Control # 13 primary 14 24 19 14 13 11 7 
Control# 14 primary 3 23 14 9 12 
Control # 15 primary 31 
Control # 17 primary 19 23 12 20 17 26 16 
Control # 20 primary 30 22 21 22 18 26 16 
Control # 21 primary 32 24 23 23 32 27 
Control # 22 primary 33 35 25 36 29 40 28 
T-test 0.9625756 0.1403264 0.1582157 0.3791422 0.5534169 0.1832134 
Paired t-test 0.3064629 0.2737201 0.140794 0.0547473 0.1587879 0.0066924 
Ranges 14-53 3.0-67 12.0-25 14-36 11 .0-34 7.0-40 5.0-28 
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Blastic colony results of normal individuals 








Plated at l x l 04/ml 
NAM:ES A 
Control# 2 primary 154 
Control # 3 primary 3 
Control # 6 primary 
Control # 11 primary 10 
Control# 21 primary 138 
Control# 24 primary 139 
Control # 25 primary 184 
Control # 26 primary 172 
Control # 27 primary 17 4 
1 x l 04 selected cells were layered onto stroma that has been 
supplemented with FGF and HS for 21 days. The cells were 
incubated for 2 hours for optimal adherence. 
Non- adhered cells were removed and cultured in CFU-GM assay. 
B C D E F G 
159 218 260 128 271 146 
21 62 51 60 43 45 
48 16 41 7 24 8 
140 113 144 131 177 137 
112 103 91 81 169 99 
102 99 93 113 71 
135 121 197 168 238 207 
115 117 185 176 219 203 
T-test 0.5724658 0.9365776 0.4462710.4954703 0.241792 0.316814 
Paired t-test 0.2568907 0.8563509 0.0659778 0.1278488 0.0286962 0.0198601 
Ranges 3.0-184 21-159 16-218 41-260 7-176 43-271 8-207 
Control CD34+ cells on to control stroma (without bFGF 
treatment) 
Controls CFU-bl x 104/ml CFU-GMs 
Control #17 90 80 
Control #20 103 258 
Control #24 130 337 
Control #22 84 141 
Control #26 139 126 
Control #31 72 167 
Control #33 24 249 
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0.5 x 106 cells cultured with different FGF concentrations, 
in medium supplemented with 15% FCS, 2 x l 0·1 M 
A suspension obtained by incubation of stromal cells with 
5% trypsin for 10 minutes and inactivated by addition of cold 4C FCS, 
and cells counted on the particle counter. 
B C D E F G 
0.54 0.45 0.75 0.4 1.04 0.52 
0.29 0.9 1.19 1.16 1.89 1.61 
0.25 0.35 0.38 0.39 0.8 0.33 
0.15 0.4 0.97 0.29 0.44 0.98 
0.12 0.94 0.28 1.2 0.46 1.52 
0.81 1.99 4.11 1.14 0.61 1.11 
0.35 0.27 0.65 0.45 0.88 0.43 
0.96 1.1 1.64 0.91 3.92 1.42 
0.52 0.56 1.1 0.85 1.3 0.93 
0.24 0.32 0.27 0.35 0.34 0.51 
1.45 1.38 1.41 1.36 2.6 1.47 
1.67 1.24 2.71 1.69 3.3 1.76 
0.56 0.95 1.26 0.55 1.53 1.55 
0.9832539 0.2610448 0.1836795 0.1680489 0.0731182 0.2841629 
0.9808519 0.0828389 0.036821 0.0897597 0.0327583 0.168224 
0.12-1.67 0.32-1.99 0.27-4.11 0.29-1.36 0.44-1.89 0.33-1.76 
76 
Confluence of normal individual at 3 weeks 
Confluence @ 3 weeks (0/o) 
Blank 0.2ng + HS 0.2ng 2ng + HS 2ng 20ng+ HS 20ng 
Control I 60 45 45 65 60 85 85 
Control 2 55 50 50 75 65 90 90 
Control 3 40 40 30 55 50 70 70 
Control 4 55 45 50 65 60 75 75 
Control 5 65 35 30 70 60 95 98 
Control 6 30 50 50 80 65 86 75 
Control 8 50 50 55 80 80 90 70 
Control 9 55 60 60 85 80 90 90 
Control 11 65 45 45 95 70 80 70 
Control 13 60 50 55 70 70 95 80 
Control 15 60 70 79 
Control 17 50 65 80 
Control 20 45 85 99 
Control 22 60 50 95 
Control 24 50 60 60 
Control 26 45 70 75 
Control 29 50 65 65 
Control 30 50 75 70 
Control 30 65 80 90 
Control 31 40 70 75 
Control 32 55 70 65 
Control 33 55 65 70 
Median 55 47.5 50 70 65 80 77.5 
T test 0.08250223 0.11695085 l.42432E-07 0.00060715 0.00489634 l.0847E-08 
Paired t test 6.7574E-10 
Ranges 30-65 35-60 30-60 50-95 50-80 65-99 70-98 
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Stromal cell numbers and CFU-F results of patients 
BMT PATIENTS RESULTS 
Patients Dia&nosis BMT Stromal cell numbers x 10
6
/ 2ml CFU-Fs ~er 10
6 15ml 
Blank 2ng 20ng Blank 2ng 20ng 
Patient 1 AML-M2 Allo 0.28 0.25 0.46 6 6 5 
Patient 2 NHL Allo 0.96 2.03 2.42 12 14 13 
Patient 3 CML Allo 0.43 0.72 1.14 n/a 
Patient 4 NHL-CatD Allo 1.2 1.6 2.5 19 18 28 
Patient 5 NHL-CatC Allo 0.53 1.29 1.79 23 24 24 
Patient 6 ALL Allo 1.54 2.8 3.35 28 33 33 
Patient 7 AML Auto 0.64 l.75 2.65 7 8 8 
Patients NHL Allo 0.28 0.67 2.02 7 6 8 
Patient 9 NHL Allo 0.6 0.52 1.03 19 18 17 
PatientlO SAA Allo 1.73 2.01 2.2 23 24 25 
Patient 11 NHL Allo Nia 6 7 4 
Patient 13 ALL Allo 0.67 0.93 1.41 7 12 10 
Patient14 Bl-NHL Allo 1.5 2.64 3.43 5 4 5 
Patient15 MDS Allo 1.33 1.89 2.54 6 5 8 
Patient 16 NHL Allo 0.65 0.9 1.38 7 3 5 
Median values 0.66 1.445 2.11 7 10 9 
T test 0.03773 0.07075 0.8797 0.82871 
0.00023 
Paired t test 0.0005 8.2E-06 0.45146 0.1326 
Ranges 0.28-1.73 0.25-2.8 0.46-3.43 5.0-28.0 3.0-33.0 4.0-33 .0 
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Demographic Data of Patients 
PATIENTS AGE GENDER DIAGNOSIS Time post-Tx 
Patientl 46 Male AML-M2 12 months 
Patient 2 37 Male NHL 6 months 
Patient 3 29 Male CML 6 months 
Patient 4 52 Female AML 12 months 
Patient 5 48 Male NHL-Cat-C 11 months 
Patient 6 17 Male ALL 12 months 
Patient 7 43 Male AML-M2 6 months 
Patient 8 37 Male NHL 6 months 
Patient 9 57 Female NHL 6 months 
PatientlO 17 Male SAA 6 months 
Patient 11 51 Female NHL 6 months 
Patient 12 35 Male AML 48 months 
Patient 13 45 Female ALL 6 months 
Patient 14 23 Male NHL 6 months 
Patient 15 42 Male MOS 6 months 




Clinical Data of Transplantation Patients 
Patients InfusedCD34+ x 106/kg Selected CD34+ (%) Infused MNC x 108/kg CFU-GM X 104/kg 
Patient 1 0.8 98 .02 5.3 148.6 
Patient2 0.29 INS 4.69 3.1 
Patient 3 0.83 INS 6.97 0 
Patient 4 0.55 82.93 4.2 3.36 
Patient 5 0.92 INS 6.39 6.4 
Patient 6 0 66.38 106.5 
Patient 7 0.77 INS 6.16 35.8 
Patient 8 3.76 92 .6 3.76 12.9 
Patient 9 2.67 97.69 4.15 2.28 
PatientlO 3.47 98.34 7.62 24.4 
Patient 11 2.61 83 .96 8.68 38 .8 
Patient12 0 INS 0 
Patient13 6.47 98.36 11.59 56.7 
Patient14 6.2 81.9 8.71 379.7 
Patient15 13.57 84.47 13 .02 83.3 
Patient16 3.08 98.48 9.81 33.3 
Median 1.765 92.6 6.68 28.85 
TTest 0.000987362 
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Appearance of Stroma at 3 weeks 
Patients Diagnosis BMT Culture Blank(%) 2ng (%) 20ng (%) 
Patient 1 AML-M2 Auto Blank 45 70 98 
Patient 2 NHL Alla Blank 50 65 90 
Patient 3 NHL Alla Blank 20 70 85 
Patient 4 NHL-CatD Alla Blank 40 70 95 
Patient 5 NHL-CatC Alla Blank 20 70 92 
Patient 6 ALL Alla Blank 50 65 80 
Patient 7 AML Auto Blank 55 80 90 
Patient 8 NHL Auto Blank 45 60 76 
Patient9 NHL Auto Blank 30 50 75 
Patient 10 SAA Allo Blank 50 75 89 
Patient 11 NHL Alla Blank 10 25 30 
Patient12 ALL Allo Blank 0 0 20 
Patient13 ALL Alla Blank 30 40 55 
Patient14 BL-NHL Allo Blank 40 55 70 
Patient15 MDS Blank 45 60 65 
Patient16 NHL Blank 30 45 40 
Median 40 62.5 78 
T test 0.0028049 0.0578237 
1.645E-05 
Paired T test l.142E-05 4.203E-07 
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